[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 166501
1. Inagaki A, Ishida T, Ishii T, Komatsu H, Iida S, Ding J, Yonekura K, Takeuchi S, Takatsuka Y, Utsunomiya A, Ueda R: Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors. Int J Cancer; 2006 Jun 15;118(12):3054-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum Th1-, Th2- and regulatory T cells-associated cytokines in adult T-cell leukemia/lymphoma: high interleukin-5 and -10 levels are significant unfavorable prognostic factors.
  • Patients with adult T-cell leukemia/lymphoma (ATLL) are in a severely immunocompromised state.
  • Therefore, it is assumed that ATLL cells either express particular cytokines or induce their expression in host immune cells, disrupting the balanced production of cytokines and causing the host's immune system to break down.
  • We examined the levels of serum cytokines including T helper type 1- (Th1-) associated cytokines [IFN-gamma, TNF-alpha, and interleukin (IL)-2], Th2-associated cytokines (IL-4, -5 and -6) and regulatory T cell-associated cytokines (IL-10 and TGF-beta1) in 94 ATLL patients, 39 asymptomatic human T-cell lymphotropic virus type-1 (HTLV-1) carriers and 50 healthy adult volunteers, to clarify whether elevated levels of particular cytokines are associated with the prognosis of ATLL patients.
  • On multivariate analysis, high IL-5 and IL-10 levels were independent and significant unfavorable prognostic factors among the ATLL patients.
  • The IL-10 level significantly increased with disease progression at each step from asymptomatic HTLV-1 carrier to ATLL of the indolent variant (chronic and smoldering subtypes) to ATLL of the aggressive variant (acute and lymphoma subtypes).
  • Furthermore, high IL-10 was significantly associated with high lactate dehydrogenase (LDH), indicating that the IL-10 level reflects the tumor burden.
  • The IL-5 level was not associated with disease progression nor LDH.
  • Among ATLL patients with the aggressive variant, high IL-5, but not high IL-10, was an independent and significant unfavorable prognostic factor on multivariate analysis.
  • Measurement of serum IL-5 and IL-10 levels is useful for predicting the prognosis and for determining a suitable treatment strategy for ATLL patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Interleukin-10 / blood. Interleukin-5 / blood. Leukemia, T-Cell / immunology. Th1 Cells / immunology. Th2 Cells / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Interferon-gamma / blood. Interleukin-2 / blood. Interleukin-4 / blood. Interleukin-6 / blood. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Multivariate Analysis. Predictive Value of Tests. Prognosis. Transforming Growth Factor beta / blood. Tumor Necrosis Factor-alpha / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16425276.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Interleukin-2; 0 / Interleukin-5; 0 / Interleukin-6; 0 / Transforming Growth Factor beta; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 207137-56-2 / Interleukin-4; 82115-62-6 / Interferon-gamma; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


2. Shimauchi T, Kabashima K, Tokura Y: Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Sci; 2008 Jan;99(1):98-106
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells.
  • Adult T cell leukemia/lymphoma (ATL) cells share the CD4(+)CD25(+) phenotype with regulatory T (Treg) cells.
  • However, it is still controversial whether ATL cells are Treg cells.
  • The aim of the present study was to investigate the Treg nature of ATL cells obtained from peripheral blood and skin tumors in terms of their phenotype and function.
  • By flow cytometry and immunohistochemistry, the expression of the Treg-associated molecule cytotoxic T lymphocyte-associated antigen (CTLA)-4 and Foxp3 was examined in freshly isolated circulating and skin-infiltrating tumor cells from 21 ATL patients with skin eruptions.
  • The potentiality of ATL cells as Treg cells was further addressed by stimulating ATL cells with anti-CD3/CD28 monoclonal antibodies and monitoring CTLA-4 expression.
  • With the stimulation, even CTLA-4-low ATL cells expressed higher levels of CTLA-4 than normal CD4(+)CD25(+) cells.
  • To study function, ATL cells isolated from blood and skin tumors were tested for their ability to suppress the proliferation of autologous CD8(+) T cells stimulated with allogeneic lymphocytes.
  • ATL cells are phenotypically Treg cells in at least some patients, but lack immunoregulatory functions, at least toward CD8(+) T cells.
  • [MeSH-major] Antigens, CD / biosynthesis. Antigens, Differentiation / biosynthesis. CD8-Positive T-Lymphocytes / immunology. Forkhead Transcription Factors / biosynthesis. Leukemia-Lymphoma, Adult T-Cell / immunology. Skin Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / immunology. Antibodies, Monoclonal / pharmacology. Antigens, CD28 / immunology. Antigens, CD3 / immunology. CTLA-4 Antigen. Female. Humans. Male. Middle Aged. T-Lymphocytes, Regulatory / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17970785.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, CD28; 0 / Antigens, CD3; 0 / Antigens, Differentiation; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


3. Shiratori S, Yasumoto A, Tanaka J, Shigematsu A, Yamamoto S, Nishio M, Hashino S, Morita R, Takahata M, Onozawa M, Kahata K, Kondo T, Ota S, Wakasa K, Sugita J, Koike T, Asaka M, Kasai M, Imamura M: A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect. Biol Blood Marrow Transplant; 2008 Jul;14(7):817-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versus-leukemia/lymphoma effect.
  • Adult T cell leukemia/lymphoma (ATL) is a highly aggressive T cell malignancy, and has a poor prognosis.
  • Recently, allogeneic-hematopoietic stem cell transplantation (allo-HSCT) has been suggested to improve the outcome.
  • We retrospectively analyzed 15 patients with ATL who had received allo-HSCT in 2 institutions in Hokkaido, Japan.
  • Calcineurin inhibitor dosage was reduced and administration was discontinued abruptly in 6 of the 15 patients for disease control; as a result, 4 (66.7%) of the 6 patients achieved complete response (CR) or partial response.
  • Therefore, a graft-versus-leukemia/lymphoma (GVL) effect might be induced by discontinuation of immunosuppression.
  • Thirteen of the 15 patients were followed up by monitoring HTLV-1 proviral DNA levels.
  • In 10 of the 11 patients with positive HTLV-1 proviral DNA before allo-HSCT, HTLV-1 proviral DNA became undetectable at least once after allo-HSCT, and only 1 of the 5 patients in whom HTLV-1 proviral DNA became detectable after allo-HSCT relapsed.
  • Compared to the results of past studies, these results show that allo-HSCT greatly improved the prognosis of ATL and suggest a contribution of the induction of a GVL effect.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. HTLV-I Infections / blood. HTLV-I Infections / therapy. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Remission Induction. Retrospective Studies. Transplantation, Homologous. Viral Load

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Biol Blood Marrow Transplant. 2008 Sep;14(9):1079
  • (PMID = 18541202.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Kato K, Kanda Y, Eto T, Muta T, Gondo H, Taniguchi S, Shibuya T, Utsunomiya A, Kawase T, Kato S, Morishima Y, Kodera Y, Harada M, Japan Marrow Donor Program: Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program. Biol Blood Marrow Transplant; 2007 Jan;13(1):90-9
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic bone marrow transplantation from unrelated human T-cell leukemia virus-I-negative donors for adult T-cell leukemia/lymphoma: retrospective analysis of data from the Japan Marrow Donor Program.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from an HLA-matched related donor has been suggested to improve the poor prognosis of adult T-cell leukemia/lymphoma (ATLL).
  • However, the infusion of HTLV-I-infected cells from HTLV-I-positive related donors could lead to the development of donor-derived ATLL under immunosuppressive conditions.
  • Although most ATLL patients lack a suitable HLA-matched related donor and require an HTLV-I-negative unrelated donor, little information is currently available regarding the outcome of unrelated bone marrow transplantation (UBMT) for ATLL.
  • To evaluate the role of UBMT in treating ATLL, we retrospectively analyzed data from 33 patients with ATLL treated by UBMT through the Japan Marrow Donor Program (JMDP).
  • Overall survival (OS), progression-free survival, and cumulative incidence of disease progression and progression-free mortality at 1 year after UBMT were 49.5%, 49.2%, 18.6%, and 32.3%, respectively.
  • Our observations suggest that UBMT could represent a feasible treatment option for ATLL patients and warrant further investigation based on these risk factors.
  • [MeSH-major] Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Female. Graft Survival. Graft vs Host Disease. Graft vs Leukemia Effect / immunology. Humans. Japan. Male. Middle Aged. Retrospective Studies. Survival Analysis. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222757.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


5. Hoshi M, Ito H, Fujigaki H, Takemura M, Takahashi T, Tomita E, Ohyama M, Tanaka R, Saito K, Seishima M: Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity. Leuk Res; 2009 Jan;33(1):39-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Indoleamine 2,3-dioxygenase is highly expressed in human adult T-cell leukemia/lymphoma and chemotherapy changes tryptophan catabolism in serum and reduced activity.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by human T-cell lymphotropic virus type 1 (HTLV-1).
  • In this study, we investigated the IDO expression in ATLL cells and the effect of chemotherapy on IDO-initiating l-TRP catabolism in patients with ATLL.
  • Serum l-kynurenine (l-KYN) concentrations, l-KYN/l-TRP ratio, and the level of IDO mRNA expression in ATLL cells were significantly increased in ATLL patients compared to those in healthy and HTLV-positive carrier subjects.
  • On the other hand, l-TRP level was significantly decreased in ATLL patients compared to that in healthy subjects.
  • In the immunohistochemical staining, IDO was strongly expressed in cytoplasm of ATLL cells.
  • These data provide evidence that IDO is highly expressed in ATLL cells, and that IDO-initiating l-TRP catabolism changes with chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Indoleamine-Pyrrole 2,3,-Dioxygenase / metabolism. Leukemia-Lymphoma, Adult T-Cell / enzymology. Tryptophan / blood
  • [MeSH-minor] Adult. Aged. Base Sequence. DNA Primers. Female. Humans. Immunohistochemistry. Male. Middle Aged. Treatment Outcome

  • Hazardous Substances Data Bank. (L)-Tryptophan .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18639341.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Indoleamine-Pyrrole 2,3,-Dioxygenase; 8DUH1N11BX / Tryptophan
  •  go-up   go-down


6. Fujiwara H, Kawada H, Matsushita K, Hamada H, Ozaki A, Inoue H, Yoshimitsu M, Kukita T, Arimura K, Ohtsubo H, Uozumi K, Arima N, Tei C: Case of a patient with progressive adult T-cell leukemia/lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor. Int J Hematol; 2005 Nov;82(4):357-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of a patient with progressive adult T-cell leukemia/lymphoma treated successfully by reduced-intensity conditioning stem cell transplantation from an HLA-incompatible related donor.
  • A 61-year-old man with progressive adult T-cell leukemia/lymphoma (ATLL) successfully received reduced-intensity conditioning stem cell transplantation (RIST) without T-cell depletion (TCD) from his HLA-incompatible son, who had negative results for human T-lymphotropic virus type 1 (HTLV-1) (1-locus, 1-allele mismatch in the graft-versus-host [GVH] direction; 2-loci, 1-allele mismatch in the host-versus-graft direction).
  • GVH disease (GVHD) prophylaxis consisted of short-term administration of methotrexate, tacrolimus, and methylprednisolone.
  • Serial analysis of HTLV-1 proviral load by quantitative polymerase chain reaction analysis using whole peripheral blood demonstrated undetectable levels from day 90.
  • The results in this case suggest the potential of non-TCD RIST from an HLA-incompatible relative donor as an alternative source of hematopoietic stem cells even for an elderly patient with advanced ATLL.
  • In addition, basiliximab combined with MMF may be effective for the treatment of steroid-refractory skin GVHD without deteriorating the graft-versus-ATL effect.
  • [MeSH-major] Histocompatibility Testing. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / therapy. Stem Cell Transplantation
  • [MeSH-minor] B-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Graft vs Host Reaction. HLA Antigens / immunology. Humans. Male. Middle Aged. Transplantation Chimera. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16298831.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HLA Antigens
  •  go-up   go-down


7. Yamasaki R, Miyazaki Y, Moriuchi Y, Tsutsumi C, Fukushima T, Yoshida S, Taguchi J, Inoue Y, Matsuo E, Imaizumi Y, Imanishi D, Fujimoto T, Tsushima H, Honda S, Hata T, Tsukasaki K, Tomonaga M: Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma. Leukemia; 2007 Jun;21(6):1212-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small number of HTLV-1-positive cells frequently remains during complete remission after allogeneic hematopoietic stem cell transplantation that are heterogeneous in origin among cases with adult T-cell leukemia/lymphoma.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) can provide long-term remission for patients with adult T-cell leukemia/lymphoma (ATLL) caused by human retrovirus, human T-lymphocyte virus (HTLV-1).
  • To understand how HTLV-1-positive cells including ATLL cells were suppressed by allo-HSCT, we examined HTLV-1 provirus load and residual ATLL cells in peripheral blood of transplant recipients using PCR-based tests.
  • We found that the copy number of HTLV-1 genome, called provirus, became very small in number after allo-HSCT; however, in most cases, provirus did not disappear even among long-term survivors.
  • Tumor-specific PCR tests demonstrated that most of HTLV-1-positive cells that remained long after transplantation were not primary ATLL cells but donor-derived HTLV-1-positive cells.
  • We also found a case having very low amount of residual disease in peripheral blood even long after transplantation.
  • There was only one recipient in whom we failed to show the presence of HTLV-1 genome and antibody against HTLV-1 even with an extensive search, which strongly suggested the elimination of HTLV-1 after allo-HSCT.
  • These results demonstrated that after allo-HSCT the small amount of residual HTLV-1-positive cells were heterogeneous in origin and that long-term disease control for ATLL could be obtained without the complete elimination of HTLV-1.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Humans. Polymerase Chain Reaction. Remission Induction. Tissue Donors. Transplantation, Homologous. Viral Load

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410191.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


8. Karube K, Aoki R, Sugita Y, Yoshida S, Nomura Y, Shimizu K, Kimura Y, Hashikawa K, Takeshita M, Suzumiya J, Utsunomiya A, Kikuchi M, Ohshima K: The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma. Mod Pathol; 2008 May;21(5):617-25

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The relationship of FOXP3 expression and clinicopathological characteristics in adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma is an aggressive malignant disease associated with regulatory T cells as discussed in some recent reports.
  • We analyzed the expression of FOXP3, a key molecule of regulatory T cells, in adult T-cell leukemia/lymphoma and its association with clinicopathological features.
  • Of 169 adult T-cell leukemia/lymphoma cases examined, 60 (36%) showed FOXP3 expression in lymphoma cells.
  • Morphologically, 22 cases were classified as anaplastic large cell variant and 147 as pleomorphic cell variant.
  • Only 1 (5%) of the anaplastic large cell variant cases and 59/147 (40%) of the pleomorphic cell variant cases expressed FOXP3.
  • Epstein-Barr virus-infected cells were significantly more frequently found in FOXP3(+) cases (23/60; 38%) than in FOXP3(-) cases (12/109; 11%) (P<0.0001).
  • Clinically, FOXP3(+) and FOXP3(-) cases did not differ significantly in age distribution, clinical stage, lactate dehydrogenase and calcium in serum and overall survival.
  • FOXP3 expression in adult T-cell leukemia/lymphoma thus reflects morphological features and is clinically and pathologically associated with an immunosuppressive state.
  • [MeSH-major] Forkhead Transcription Factors / biosynthesis. Leukemia-Lymphoma, Adult T-Cell / immunology. Leukemia-Lymphoma, Adult T-Cell / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Southern. Epstein-Barr Virus Infections / metabolism. Female. Herpesvirus 4, Human. Humans. Immunohistochemistry. In Situ Hybridization. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246047.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


9. Takasaki Y, Iwanaga M, Tsukasaki K, Kusano M, Sugahara K, Yamada Y, Kamihira S, Ikeda S, Tomonaga M: Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL). Leuk Res; 2007 Jun;31(6):751-7
MedlinePlus Health Information. consumer health - Anemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of visceral involvements and blood cell count abnormalities on survival in adult T-cell leukemia/lymphoma (ATLL).
  • Multiple visceral involvements and various blood cell count abnormalities are frequently manifested in adult T-cell leukemia/lymphoma (ATLL) at diagnosis.
  • We evaluated the effects of four visceral involvement (bone marrow (BM), skin, liver, spleen) and six blood cell count abnormalities (anemia, neutrophilia, thrombocytopenia, monocytosis, eosinophilia, basophilia) on the overall survival of 168 ATLL patients.
  • These data support that multiple organ involvements represent a poor prognostic factor for ATLL and provide clinical significance for BM examinations.
  • [MeSH-major] Anemia / pathology. Bone Marrow / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukocyte Disorders / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver / pathology. Male. Middle Aged. Prognosis. Retrospective Studies. Skin / pathology. Spleen / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17188352.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Yonekura K, Kanekura T, Kanzaki T, Utsunomiya A: Crusted scabies in an adult T-cell leukemia/lymphoma patient successfully treated with oral ivermectin. J Dermatol; 2006 Feb;33(2):139-41
MedlinePlus Health Information. consumer health - Scabies.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crusted scabies in an adult T-cell leukemia/lymphoma patient successfully treated with oral ivermectin.
  • We report an adult T-cell leukemia/lymphoma (ATL) patient whose crusted scabies was successfully treated with oral ivermectin.
  • [MeSH-major] Ivermectin / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Scabies / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556285.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 70288-86-7 / Ivermectin
  •  go-up   go-down


11. Miyata T, Yonekura K, Utsunomiya A, Kanekura T, Nakamura S, Seto M: Cutaneous type adult T-cell leukemia/lymphoma is a characteristic subtype and includes erythema/papule and nodule/tumor subgroups. Int J Cancer; 2010 Mar 15;126(6):1521-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous type adult T-cell leukemia/lymphoma is a characteristic subtype and includes erythema/papule and nodule/tumor subgroups.
  • We first analyzed the genomic profile of cutaneous type adult T-cell leukemia/lymphoma (ATLL) in an attempt to clarify its clinical and biological characteristics.
  • Furthermore, cases with generalized nodule/tumor lesions tended to progress to aggressive ATLL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin Neoplasms / genetics. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 13 / genetics. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 7 / genetics. Comparative Genomic Hybridization. Erythema / genetics. Erythema / pathology. Female. Humans. Male. Middle Aged. Prognosis. Skin / metabolism. Skin / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19739121.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Ratner L, Harrington W, Feng X, Grant C, Jacobson S, Noy A, Sparano J, Lee J, Ambinder R, Campbell N, Lairmore M, AIDS Malignancy Consortium: Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. PLoS One; 2009;4(2):e4420
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma.
  • BACKGROUND: Human T-cell leukemia virus-associated adult T-cell leukemia-lymphoma (ATLL) has a very poor prognosis, despite trials of a variety of different treatment regimens.
  • Virus expression has been reported to be limited or absent when ATLL is diagnosed, and this has suggested that secondary genetic or epigenetic changes are important in disease pathogenesis.
  • METHODS AND FINDINGS: We prospectively investigated combination chemotherapy followed by antiretroviral therapy for this disorder.
  • Nineteen patients were prospectively enrolled between 2002 and 2006 at five medical centers in a phase II clinical trial of infusional chemotherapy with etoposide, doxorubicin, and vincristine, daily prednisone, and bolus cyclophosphamide (EPOCH) given for two to six cycles until maximal clinical response, and followed by antiviral therapy with daily zidovudine, lamivudine, and alpha interferon-2a for up to one year.
  • Seven patients were on study for less than one month due to progressive disease or chemotherapy toxicity.
  • During chemotherapy induction, viral RNA expression increased (median 190-fold), and virus replication occurred, coincident with development of disease progression.
  • CONCLUSIONS: EPOCH chemotherapy followed by antiretroviral therapy is an active therapeutic regimen for adult T-cell leukemia-lymphoma, but viral reactivation during induction chemotherapy may contribute to treatment failure.
  • Alternative therapies are sorely needed in this disease that simultaneously prevent virus expression, and are cytocidal for malignant cells.
  • [MeSH-major] Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / virology. Virus Activation
  • [MeSH-minor] Adult. Antiviral Agents / pharmacology. Antiviral Agents / therapeutic use. DNA-Directed RNA Polymerases / metabolism. Disease Progression. Disease-Free Survival. Humans. Middle Aged. RNA, Viral / metabolism. Time Factors. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Eur J Haematol. 2008 Sep;81(3):209-17 [18510697.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2852-9 [15353320.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Leuk Res. 1992;16(5):435-41 [1625468.001]
  • [Cites] J Gen Virol. 1993 Nov;74 ( Pt 11):2531-7 [8245871.001]
  • [Cites] Blood. 1995 Apr 1;85(7):1865-70 [7703492.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Virology. 2005 Aug 15;339(1):1-11 [15964046.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] Leuk Lymphoma. 2005 Nov;46(11):1553-9 [16236609.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):381-7 [16052518.001]
  • [Cites] Adv Immunol. 2006;90:83-131 [16730262.001]
  • [Cites] Drug News Perspect. 2006 May;19(4):201-9 [16823495.001]
  • [Cites] Curr Drug Targets. 2006 Oct;7(10):1341-7 [17073596.001]
  • [Cites] Trends Mol Med. 2007 Jan;13(1):23-31 [17126603.001]
  • [Cites] Biol Blood Marrow Transplant. 2007 Jan;13(1):90-9 [17222757.001]
  • [Cites] Blood. 2007 Mar 1;109(5):1857-61 [17105812.001]
  • [Cites] Int J Cancer. 2007 May 1;120(9):2052-7 [17278106.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] J Virol. 1999 Dec;73(12):10289-95 [10559346.001]
  • [Cites] J Clin Oncol. 1999 Apr;17(4):1244 [10561185.001]
  • [Cites] J Infect Dis. 2001 Jan 15;183(2):197-205 [11120926.001]
  • [Cites] Blood. 2001 Feb 15;97(4):987-93 [11159527.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Antivir Ther. 2001;6 Suppl 3:25-44 [11678471.001]
  • [Cites] Blood. 2002 Jan 1;99(1):88-94 [11756157.001]
  • [Cites] J Infect Dis. 2002 Mar 1;185(5):691-5 [11865428.001]
  • [Cites] Blood. 2002 Apr 15;99(8):2685-93 [11929754.001]
  • [Cites] J Virol. 2002 Sep;76(18):9389-97 [12186921.001]
  • [Cites] Blood. 2007 Jul 15;110(2):695-708 [17389762.001]
  • [Cites] Cancer Sci. 2008 Jan;99(1):98-106 [17970785.001]
  • [Cites] Blood. 2003 Jun 15;101(12):4653-9 [12609827.001]
  • (PMID = 19204798.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00041327
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / U01 CA070019; United States / NCI NIH HHS / CA / U01 CA083038; United States / NCI NIH HHS / CA / U01 CA071375; United States / NCI NIH HHS / CA / U01 CA070054; United States / NCI NIH HHS / CA / CA10521; United States / NCI NIH HHS / CA / U01 CA070062; United States / NCI NIH HHS / CA / P01 CA100730-07
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / RNA, Viral; EC 2.7.7.6 / DNA-Directed RNA Polymerases
  • [Other-IDs] NLM/ PMC2636875
  •  go-up   go-down


13. Amano M, Kurokawa M, Ogata K, Itoh H, Kataoka H, Setoyama M: New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types. J Dermatol; 2008 May;35(5):270-5
Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] New entity, definition and diagnostic criteria of cutaneous adult T-cell leukemia/lymphoma: human T-lymphotropic virus type 1 proviral DNA load can distinguish between cutaneous and smoldering types.
  • Adult T-cell leukemia/lymphoma (ATLL) has been divided into four subtypes up to now: (i) acute;.
  • (ii) lymphoma;.
  • Skin lesion(s) may be present and the cases showing less than 5% abnormal T-lymphocytes in peripheral blood without involvement of other organs, have been classified as smoldering ATLL.
  • However, this type of ATLL with skin manifestations had a worse prognosis than that without skin lesions.
  • This study aimed to define and distinguish cutaneous ATLL lacking nodal lymphoma and leukemic change from smoldering ATLL.
  • We propose an entity of cutaneous ATLL, which has less than 5% abnormal T lymphocyte in peripheral blood, a normal lymphocyte count (i.e.
  • At least one of the histologically proven skin lesions should be present accompanying monoclonal integration of human T-cell lymphotropic virus type 1 (HTLV-1) proviral DNA in the skin lesion.
  • Blood samples were collected from 41 HTLV-1-infected patients, 21 asymptomatic carriers, 16 patients with cutaneous ATLL and four patients with smoldering ATLL.
  • HTLV-1 proviral loads, soluble interleukin-2 receptors and other parameters were examined in each case.
  • HTLV-1 proviral DNA loads in smoldering ATLL group are significantly higher than those in asymptomatic carrier and cutaneous ATLL group.
  • Cutaneous ATLL may be a distinct entity that should be separated from smoldering ATLL clinically and virologically.
  • [MeSH-major] DNA, Viral / analysis. Human T-lymphotropic virus 1 / genetics. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Proviruses / genetics. Viral Load

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477226.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


14. Kozako T, Yoshimitsu M, Fujiwara H, Masamoto I, Horai S, White Y, Akimoto M, Suzuki S, Matsushita K, Uozumi K, Tei C, Arima N: PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia; 2009 Feb;23(2):375-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.
  • Adult T-cell leukemia/lymphoma (ATLL) develops after infection with human T-cell leukemia virus-1 (HTLV-1) after a long latency period.
  • To determine whether the PD-1/PD-L1 pathway could be involved in the establishment of persistent HTLV-1 infections and immune evasion of ATLL cells in patients, we examined PD-1/PD-L1 expression on cells from 27 asymptomatic HTLV-1 carriers (ACs) and 27 ATLL patients in comparison with cells from 18 healthy donors.
  • PD-1 expression on HTLV-1-specific CTLs from ACs and ATLL patients was dramatically elevated.
  • In addition, PD-1 expression was significantly higher on CD8+ T cells along with cytomegalovirus (CMV)- and Epstein-Barr virus (EBV)-specific CTLs in ATLL patients compared with ACs and control individuals.
  • Primary ATLL cells in 21.7% of ATLL patients expressed PD-L1, whereas elevated expression was not observed in cells from ACs.
  • Finally, in functional studies, we observed that an anti-PD-L1 antagonistic antibody upregulated HTLV-1-specific CD8+T-cell response.
  • These observations suggest that the PD-1/PD-L1 pathway plays a role in fostering persistent HTLV-1 infections, which may further ATLL development and facilitate immune evasion by ATLL cells.
  • [MeSH-major] Antigens, CD / analysis. Apoptosis Regulatory Proteins / analysis. Leukemia-Lymphoma, Adult T-Cell / immunology
  • [MeSH-minor] Antigens, CD274. CD8-Positive T-Lymphocytes / chemistry. CD8-Positive T-Lymphocytes / immunology. Case-Control Studies. Disease Progression. Human T-lymphotropic virus 1. Humans. Programmed Cell Death 1 Receptor. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18830259.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD274; 0 / Apoptosis Regulatory Proteins; 0 / CD274 protein, human; 0 / PDCD1 protein, human; 0 / Programmed Cell Death 1 Receptor
  •  go-up   go-down


15. Phillips AA, Shapira I, Willim RD, Sanmugarajah J, Solomon WB, Horwitz SM, Savage DG, Bhagat G, Soff G, Zain JM, Alobeid B, Seshan VE, O'Connor OA: A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer; 2010 Jul 15;116(14):3438-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score.
  • BACKGROUND: To define the clinicopathologic and prognostic features of patients with human T-cell lymphotropic virus type-1 (HTLV-1)-associated adult T-cell leukemia/lymphoma (ATLL) in North America, standard criteria were used to identify patients with ATLL.
  • The acute subtype predominated (68.5%).
  • Although the International Prognostic Index and Prognostic Index for peripheral T-cell lymphoma unspecified identified subsets of patients, these models were not completely predictive.
  • A recursive partitioning analysis was performed on the data, which successfully identified 3 prognostic categories based on Eastern Cooperative Oncology Group performance status, stage, age, and calcium level at diagnosis.
  • CONCLUSIONS: This series proposed a new prognostic model for patients with HTLV-1-associated ATLL and confirmed a poor outcome for these patients in North America.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Prognosis. United States

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Cancer Society.
  • (PMID = 20564100.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


16. Kchour G, Tarhini M, Sharifi N, Farid R, Khooei AR, Shirdel A, Afshari JT, Sadeghian A, Otrock Z, Hermine O, El-Sabban M, Bazarbachi A: Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma. Leuk Lymphoma; 2008 Feb;49(2):265-70

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased microvessel density in involved organs from patients with HTLV-I associated adult T cell leukemia lymphoma.
  • Adult T-cell leukemia-lymphoma (ATLL) is a rapidly progressive lymphoproliferative disorder secondary to infection with the human T cell lymphotropic virus type I (HTLV-I).
  • We have previously shown that ATLL derived cells secrete high levels of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF), induce endothelial tube formation in vitro and establish functional gap junction-mediated communication with endothelial cells.
  • We also demonstrated that plasma from ATLL and tropical spastic paraparesis/HTLV-I associated myelopathy patients exhibit very high levels of VEGF and b-FGF.
  • Recently, we showed that treatment with the combination of zidovudine and interferon alpha reduced both HTLV-I proviral load and importantly VEGF plasma levels suggesting a potential anti-angiogenic effect of this therapy.
  • In this report, we evaluated microvessel density (MVD) in involved organs from 20 patients with ATLL, as compared to normal organs from matched controls.
  • We show evidence of significantly increased MVD in all tested involved organs from ATLL patients, suggesting that angiogenesis plays an important role in the development or organ invasion of ATLL, and could represent a potentially interesting target for anti-angiogenic therapy of ATLL.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / etiology. Leukemia-Lymphoma, Adult T-Cell / pathology. Neovascularization, Pathologic
  • [MeSH-minor] Adult. Aged. Bone Marrow / blood supply. Capillaries. Case-Control Studies. Female. Humans. Immunohistochemistry. Lymph Nodes / blood supply. Male. Middle Aged. Skin / blood supply. Testis / blood supply

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18231912.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


17. Kameda T, Shide K, Shimoda HK, Hidaka T, Kubuki Y, Katayose K, Taniguchi Y, Sekine M, Kamiunntenn A, Maeda K, Nagata K, Matsunaga T, Shimoda K: Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma. Int J Hematol; 2010 Sep;92(2):320-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of gain-of-function JAK1 and JAK3 mutations in adult T cell leukemia/lymphoma.
  • Somatic JAK1 mutations are found in 18% of adult precursor T acute lymphoblastic leukemias and somatic JAK3 mutations are found in 3.3% of cutaneous T cell lymphomas.
  • Adult T cell leukemia/lymphoma (ATLL) is a type of T cell neoplasm, and activation of JAK/STAT pathways is sometimes observed in them.
  • We investigated JAK1 and JAK3 mutations in 20 ATLL patients.
  • JAK1 and JAK3 mutations are unlikely involved in the leukemogenesis of ATLL.
  • [MeSH-major] Janus Kinase 1 / genetics. Janus Kinase 3 / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adult. Cell Differentiation. Cell Proliferation. DNA Mutational Analysis. Humans. Japan. Polymorphism, Single Nucleotide

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20697856.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Janus Kinase 1; EC 2.7.10.2 / Janus Kinase 3
  •  go-up   go-down


18. Delhommeau F, Huguet S, Gachet J, van den Akker J, Lagrange M: Primary plasma cell leukemia mimicking an adult T-cell leukemia-lymphoma: a case report. Acta Cytol; 2010 Mar-Apr;54(2):187-9
Genetic Alliance. consumer health - Plasma cell leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary plasma cell leukemia mimicking an adult T-cell leukemia-lymphoma: a case report.
  • BACKGROUND: Malignant plasma cells ofmultiple myeloma (MM), or plasma cell leukemia (PCL), may present highly variable morphologic aspects.
  • Adult T-cell leukemia-lymphoma (ATLL) is a peripheral T-cell neoplasm composed of highly pleomorphic lymphoid cells.
  • We report an unusual case ofprimary PCL with misleading cellular morphology and some clinical and biologic similarities simulating ATLL.
  • Blood cell count showed anemia and thrombocytopenia and a hyperleukocytosis composed of deeply basophilic cells with a polylobulated nucleus resembling flower cells.
  • An ATLL diagnosis was given at first, without ruling out the possibility of a PCL diagnosis.
  • Immunophenotyping was key to the diagnosis of primary PCL.
  • CONCLUSION: Some clinical and biological overlap may exist between PCL and ATLL, leading to a false diagnosis or delaying a correct one.
  • An accurate cytologic analysis leading to a rapid detection of plasma cell markers is essential for an early diagnosis.
  • [MeSH-major] Leukemia, Plasma Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Plasma Cells / pathology
  • [MeSH-minor] Adult. Antigens, CD38 / analysis. Diagnosis, Differential. Humans. Male. Syndecan-1 / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20391976.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Syndecan-1; EC 3.2.2.5 / Antigens, CD38
  •  go-up   go-down


19. Evens AM, Ziegler SL, Gupta R, Augustyniak C, Gordon LI, Mehta J: Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma. Clin Lymphoma Myeloma; 2007 Jul;7(7):472-4
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained hematologic and central nervous system remission with single-agent denileukin diftitox in refractory adult T-cell leukemia/lymphoma.
  • Human T-lymphotrophic virus-1-associated adult T-cell leukemia/lymphoma (ATLL) is a rare and often fatal disease.
  • Initial treatment often includes zidovudine/interferon (IFN)-based therapy, although disease remission is typically not complete or durable.
  • This study reports on a 55-year-old man with relapsed/refractory leukemic-phase ATLL including significant central nervous system (CNS) disease with resistance to previous zidovudine/IFN and arsenic trioxide/IFN treatment.
  • The patient experienced a rapid hematologic and CNS clinical response with single-agent denileukin diftitox therapy (18 microg/kg per day for 5 days).
  • The patient subsequently underwent matched sibling reduced-intensity allogeneic transplantation and remains disease free.
  • Further study examining denileukin diftitox in patients with relapsed/refractory ATLL is warranted.
  • [MeSH-major] Bone Marrow Transplantation. Central Nervous System Neoplasms / therapy. Diphtheria Toxin / administration & dosage. Hematologic Neoplasms / therapy. Interleukin-2 / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / therapy

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17875237.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arsenicals; 0 / Diphtheria Toxin; 0 / Interleukin-2; 0 / Oxides; 0 / Recombinant Fusion Proteins; 25E79B5CTM / denileukin diftitox; 4B9XT59T7S / Zidovudine; 9008-11-1 / Interferons; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


20. Bittencourt AL, da Graças Vieira M, Brites CR, Farre L, Barbosa HS: Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients. Am J Clin Pathol; 2007 Nov;128(5):875-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma in Bahia, Brazil: analysis of prognostic factors in a group of 70 patients.
  • The purpose of this study was to evaluate whether subdivision of adult T-cell leukemia/lymphoma (ATL) on the basis of clinical types, skin involvement, histologic features, cell size, and proliferative index (PI) was clinically relevant.
  • The following variables were adversely related to survival: acute, lymphoma, and PCT types; absence of skin lesions; large cells; and PI more than 18%.
  • The MST of the PCT type (21 months) was shorter than that of the smoldering type, confirming the importance of clearly defining these 2 types of ATL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Brazil / epidemiology. Child. Female. Humans. Male. Middle Aged. Prognosis. Skin / pathology. Survival Rate

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17951212.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


21. Harasawa H, Yamada Y, Hieshima K, Jin Z, Nakayama T, Yoshie O, Shimizu K, Hasegawa H, Hayashi T, Imaizumi Y, Ikeda S, Soda H, Soda H, Atogami S, Takasaki Y, Tsukasaki K, Tomonaga M, Murata K, Sugahara K, Tsuruda K, Kamihira S: Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma. Leuk Lymphoma; 2006 Oct;47(10):2163-73

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survey of chemokine receptor expression reveals frequent co-expression of skin-homing CCR4 and CCR10 in adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is a malignancy of mature T-cell origin with multi-organ involvement.
  • Because the chemokine receptors play crucial roles in tissue-specific homing of mature lymphocytes, particular chemokine receptors expressed on ATLL cells may be involved in their tissue infiltration.
  • We thus performed a comprehensive survey on the chemokine receptor expression in ATLL.
  • ATLL cells expressed transcripts of CCR1, CCR4, CCR7, CCR8, CCR10 and CXCR4 but hardly expressed those of CCR2, CCR3, CCR5, CCR6, CCR9, CXCR1, CXCR2, CXCR3 and CXCR5.
  • ATLL cells migrated efficiently to the CCR4 ligand, CCL22, and moderately to the CCR10 ligands, CCL27 and CCL28.
  • Moreover, ATLL skin lesions consistently contained transcripts of CCR10 and its ligands CCL27 and CCL28 besides those of CCR4 and its ligands CCL17 and CCL22 that have been reported previously.
  • Collectively, the frequent co-expression of CCR4 and CCR10, the known pair of skin-homing chemokine receptors, may play an important role in ATLL invasion into the skin.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, T-Cell / metabolism. Lymphoma, T-Cell / metabolism. Receptors, Chemokine / biosynthesis. Skin / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071491.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CCR10 protein, human; 0 / CCR4 protein, human; 0 / Chemokines; 0 / DNA Primers; 0 / Receptors, CCR10; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


22. Alizadeh AA, Bohen SP, Lossos C, Martinez-Climent JA, Ramos JC, Cubedo-Gil E, Harrington WJ Jr, Lossos IS: Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha. Leuk Lymphoma; 2010 Jul;51(7):1200-16
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha.
  • Adult T-cell leukemia-lymphoma (ATLL) is an HTLV-1-associated lymphoproliferative malignancy that is frequently fatal.
  • We compared gene expression profiles (GEPs) of leukemic specimens from nine patients with ATLL at the time of diagnosis and immediately after combination therapy with zidovudine (AZT) and interferon alpha (IFNalpha).
  • We identified several genes anomalously over-expressed in the ATLL leukemic cells at the mRNA level, including LYN, CSPG2, and LMO2, and confirmed LMO2 expression in ATLL cells at the protein level.
  • In vivo AZT-IFNalpha therapy evoked a marked induction of interferon-induced genes accompanied by repression of cell-cycle regulated genes, including those encoding ribosomal proteins.
  • Demonstration of specific gene expression signatures associated with response to AZT-IFNalpha therapy may provide novel insights into the mechanisms of action in ATLL.
  • [MeSH-major] Anti-HIV Agents / therapeutic use. Biomarkers, Tumor / genetics. Gene Expression Profiling. Interferon-alpha / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / genetics. Zidovudine / therapeutic use
  • [MeSH-minor] Adult. Comparative Genomic Hybridization. Drug Therapy, Combination. Humans. Oligonucleotide Array Sequence Analysis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2010 Jul;51(7):1157-8 [20388057.001]
  • (PMID = 20370541.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / P30 AI073961; United States / NCI NIH HHS / CA / P30 CA124435; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA109335; United States / NCI NIH HHS / CA / R01 CA122105
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / Interferon-alpha; 0 / RNA, Messenger; 4B9XT59T7S / Zidovudine
  • [Other-IDs] NLM/ NIHMS636985; NLM/ PMC4296320
  •  go-up   go-down


23. Suzumiya J, Ohshima K, Tamura K, Karube K, Uike N, Tobinai K, Gascoyne RD, Vose JM, Armitage JO, Weisenburger DD, International Peripheral T-Cell Lymphoma Project: The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project. Ann Oncol; 2009 Apr;20(4):715-21
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The International Prognostic Index predicts outcome in aggressive adult T-cell leukemia/lymphoma: analysis of 126 patients from the International Peripheral T-Cell Lymphoma Project.
  • BACKGROUND: The International Peripheral T-cell Lymphoma Project was organized to better understand the T-cell and natural killer (NK) cell lymphomas, and our task is to present the clinicopathologic correlations and therapeutic results for adult T-cell leukemia/lymphoma (ATL).
  • PATIENTS AND METHODS: Among 1153 patients with T-cell or NK cell lymphomas, 126 patients (9.6%) with ATL were represented in this project.
  • All were categorized as aggressive ATL, i.e. acute or lymphoma type, and 87% fell into the lymphoma type.
  • CONCLUSION: Patients with aggressive ATL have a poor clinical outcome and the IPI is a useful model for predicting outcome in ATL of the lymphoma type.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19150954.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Investigator] Savage K; Connors J; Gascoyne R; Chhanabhai M; Wilson W; Jaffe E; Armitage J; Vose J; Weisenburger D; Anderson J; Ullrich F; Bast M; Hochberg E; Harris N; Levine A; Nathwani B; Miller T; Rimsza L; Montserrat E; Lopez-Guillermo A; Campo E; Cuadros M; Alvarez Ferreira J; Martinez Delgado B; Holte H; Delabie J; Rüdiger T; Müller-Hermelink K; Reimer P; Adam P; Wilhelm M; Schmitz N; Nerl C; MacLennan KA; Zinzani PL; Pileri S; Federico M; Bellei M; Coiffier B; Berger F; Tanin I; Wannakrairot P; Au W; Liang R; Loong F; Rajan S; Sng I; Tobinai K; Matsuno Y; Morishima Y; Nakamura S; Seto M; Tanimoto M; Yoshino T; Suzumiya J; Ohshima K; Kim WS; Ko YH
  •  go-up   go-down


24. Bittencourt AL, Mota K, Oliveira RF, Farré L: A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report. Am J Dermatopathol; 2009 Dec;31(8):834-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A dyshidrosis-like variant of adult T-cell leukemia/lymphoma with clinicopathological aspects of mycosis fungoides. A case report.
  • Adult T-cell leukemia/lymphoma (ATL) is an aggressive type of leukemia/lymphoma associated with the human T-cell lymphotropic virus (HTLV-I).
  • We describe an adult male patient clinically and pathologically diagnosed as mycosis fungoides and treated with chemotherapy after which complete involution of the lesions occurred.
  • The disease relapsed with confluent dyshidrosis-like vesicles on the palmoplantar regions, followed by disseminated vesiculopapules and associated lymphocytosis.
  • A serological test performed at this time revealed HTLV-I infection, and a diagnosis of chronic ATL was made.
  • Monoclonal integration of HTLV-I was detected in peripheral blood mononuclear cells by inverse long polymerase chain reaction.
  • This is the first reported vesicular cutaneous ATL with confirmation of HTLV-I proviral integration.
  • The delay that occurred in diagnosing ATL was due to the fact that mycosis fungoides and ATL may present the same clinical, histopathological, and immunohistochemical features.
  • [MeSH-major] Eczema, Dyshidrotic / pathology. HTLV-I Infections / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Mycosis Fungoides / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide. Diabetes Mellitus. Diagnosis, Differential. Doxorubicin. Human T-lymphotropic virus 1. Humans. Immunohistochemistry. Interferon-alpha / therapeutic use. Male. Polymerase Chain Reaction. Prednisone. Vincristine. Zidovudine / therapeutic use

  • Genetic Alliance. consumer health - Mycosis fungoides.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19770630.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


25. Tomoyose T, Nagasaki A, Uchihara JN, Kinjo S, Sugaya K, Onaga T, Ohshima K, Masuda M, Takasu N: Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature. Am J Hematol; 2007 Aug;82(8):748-52
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature.
  • Primary adrenal lymphoma (PAL) is very rare; the majority of cases reported previously were of B-cell origin.
  • We report a rare case of primary adrenal adult T-cell leukemia/lymphoma (primary adrenal ATLL).
  • ATLL is a highly aggressive T-cell type non-Hodgkin's lymphoma and etiologically associated with human T-cell lymphotropic virus 1 (HTLV-1).
  • Most ATLL patients present with leukemia and widespread lymphadenopathy.
  • Examination showed no peripheral lymphadenopathy, circulating lymphoma cells, hepatosplenomegaly, and skin lesions.
  • Subsequently, she underwent open adrenal biopsy and pathological diagnosis was confirmed as T-cell lymphoma.
  • The serum antibody to HTLV-1 was positive.
  • Southern blot analysis detected monoclonal integration of proviral DNA of HTLV-1 into host genome in the biopsy specimen.
  • The diagnosis of ATLL arising in adrenal glands was established.
  • Despite repeated systemic chemotherapy, the patient died of progressive disease in December 2004.
  • ATLL could primarily involve the adrenal gland and this disease entity should be included in the differential diagnosis of adrenal mass lesions.
  • [MeSH-major] Adrenal Gland Neoplasms / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology
  • [MeSH-minor] Adult. Biopsy. Female. Human T-lymphotropic virus 1 / genetics. Humans. Tomography Scanners, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17373678.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


26. Tholouli E, Liu Yin JA: Successful treatment of HTLV-1-associated acute adult T-cell leukemia lymphoma by allogeneic bone marrow transplantation: a 12 year follow-up. Leuk Lymphoma; 2006 Aug;47(8):1691-2
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of HTLV-1-associated acute adult T-cell leukemia lymphoma by allogeneic bone marrow transplantation: a 12 year follow-up.
  • [MeSH-major] Bone Marrow Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Remission Induction. Transplantation, Homologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966289.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


27. Phillips AA, Willim RD, Savage DG, Horwitz SM, Isola L, Zain JM, O'Connor OA: A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients. Leuk Lymphoma; 2009 Jun;50(6):1039-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / surgery
  • [MeSH-minor] Adult. Caribbean Region / ethnology. Female. HTLV-I Infections / complications. HTLV-I Infections / virology. Humans. Latin America / ethnology. Middle Aged. New York City. Recurrence. Retrospective Studies. Salvage Therapy. Transplantation, Autologous. Treatment Outcome


28. Narimatsu H, Murata M, Sugimoto K, Terakura S, Kinoshita T, Naoe T: Successful umbilical cord blood transplantation using a reduced-intensity preparative regimen without total body irradiation and tacrolimus plus methotrexate for prophylaxis of graft-versus-host disease in a patient with adult T-cell leukemia/lymphoma. Leuk Lymphoma; 2007 Apr;48(4):841-3
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful umbilical cord blood transplantation using a reduced-intensity preparative regimen without total body irradiation and tacrolimus plus methotrexate for prophylaxis of graft-versus-host disease in a patient with adult T-cell leukemia/lymphoma.
  • [MeSH-major] Fetal Blood / cytology. Graft vs Host Disease / prevention & control. Leukemia, T-Cell / therapy. Lymphoma, T-Cell / therapy. Methotrexate / administration & dosage. Stem Cell Transplantation / methods. Tacrolimus / administration & dosage. Transplantation Conditioning / methods

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17454652.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] WM0HAQ4WNM / Tacrolimus; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


29. Horie R, Watanabe T, Umezawa K: Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma. Drug News Perspect; 2006 May;19(4):201-9
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATL), a fatal T-cell leukemia/lymphoma resistant to chemotherapy, is caused by human T-cell leukemia/lymphoma virus type I (HTLV-1), occurring even after 50 years of clinical latency from initial transmission.
  • Constitutively activated nuclear factor kappaB (NF-kappaB) appears to be a molecular basis for the aberrant growth and cytokine gene expression observed in ATL cells, thereby serving as an ideal target in the treatment of ATL.
  • Dehydroxymethylepoxyquinomicin inhibits NF-kappaB activation in ATL cells and induces apoptotic cell death.
  • In addition, DHMEQ selectively targets HTLV-1-infected cells in the peripheral blood of virus carriers in vitro, resulting in a decreased number of infected cells.
  • We have concluded that blocking NF-kappaB is a potential strategy for the treatment and prevention of ATL.
  • As a potent NF-kappaB inhibitor, DHMEQ is a promising compound for translating this strategy into clinical medicine.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. NF-kappa B / antagonists & inhibitors
  • [MeSH-minor] Adult. Animals. Apoptosis / drug effects. Benzamides / pharmacology. Benzamides / therapeutic use. Cyclohexanones / pharmacology. Cyclohexanones / therapeutic use. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Prous Science
  • (PMID = 16823495.001).
  • [ISSN] 0214-0934
  • [Journal-full-title] Drug news & perspectives
  • [ISO-abbreviation] Drug News Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Cyclohexanones; 0 / NF-kappa B; 0 / dehydroxymethylepoxyquinomicin
  • [Number-of-references] 49
  •  go-up   go-down


30. Banerjee P, Tripp A, Lairmore MD, Crawford L, Sieburg M, Ramos JC, Harrington W Jr, Beilke MA, Feuer G: Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice. Blood; 2010 Apr 1;115(13):2640-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma development in HTLV-1-infected humanized SCID mice.
  • The molecular and genetic factors induced by human T-lymphotropic virus type-1 (HTLV-1) that initiate adult T-cell leukemia/lymphoma (ATLL) remain unclear, in part from the lack of an animal model that accurately recapitulates leukemogenesis.
  • HTLV-1-infected humanized nonobese diabetic severe combined immunodeficiency (HU-NOD/SCID) mice were generated by inoculation of NOD/SCID mice with CD34(+) hematopoietic progenitor and stem cells (CD34(+) HP/HSCs) infected ex vivo with HTLV-1.
  • HTLV-1-HU-NOD/SCID mice exclusively developed CD4(+) T-cell lymphomas with characteristics similar to ATLL and elevated proliferation of infected human stem cells (CD34(+)CD38(-)) in the bone marrow were observed in mice developing malignancies.
  • Purified CD34(+) HP/HSCs from HTLV-1-infected patient peripheral blood mononuclear cells revealed proviral integrations suggesting viral infection of human bone marrow-derived stem cells.
  • NOD/SCID mice reconstituted with CD34(+) HP/HSCs transduced with a lentivirus vector expressing the HTLV-1 oncoprotein (Tax1) also developed CD4(+) lymphomas.
  • The recapitulation of a CD4(+) T-cell lymphoma in HU-NOD/SCID mice suggests that HSCs provide a viral reservoir in vivo and act as cellular targets for cell transformation in humans.
  • This animal model of ATLL will provide an important tool for the identification of molecular and cellular events that control the initiation and progression of the lymphoma and potential therapeutic targets to block tumor development.

  • COS Scholar Universe. author profiles.
  • Jackson Laboratory JAX®Mice Database. culture/stock collections - NOD.Cg-Prkdc<scid> Il2rg<tm1Wjl>/SzJ (subscription/membership/fee required).
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Blood. 2009 Sep 24;114(13):2709-20 [19584402.001]
  • [Cites] Stem Cells. 2008 Dec;26(12):3047-58 [18818438.001]
  • [Cites] Blood. 2009 May 14;113(20):4914-7 [19246560.001]
  • [Cites] Nat Med. 2007 May;13(5):527-8 [17479090.001]
  • [Cites] J Reprod Immunol. 2000 Jul;47(2):197-206 [10924751.001]
  • [Cites] Bull Soc Pathol Exot. 2000 Jul;93(3):163-71 [11030050.001]
  • [Cites] Bone Marrow Transplant. 2000 Dec;26(11):1235-7 [11149739.001]
  • [Cites] Presse Med. 2000 Dec 23;29(40):2233-9 [11196061.001]
  • [Cites] J Cell Physiol. 2002 Feb;190(2):133-59 [11807819.001]
  • [Cites] Oncogene. 2003 Aug 11;22(33):5131-40 [12910250.001]
  • [Cites] J Virol. 2003 Nov;77(22):12152-64 [14581552.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):312-20 [14686488.001]
  • [Cites] Acta Pathol Jpn. 1979 Sep;29(5):723-38 [315153.001]
  • [Cites] Gan To Kagaku Ryoho. 1983 Feb;10(2 Pt 2):642-9 [6603818.001]
  • [Cites] Princess Takamatsu Symp. 1984;15:129-35 [6152757.001]
  • [Cites] Acta Paediatr Jpn. 1989 Aug;31(4):428-35 [2514566.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J Infect Dis. 1993 Jan;167(1):57-65 [8418183.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] Blood. 1993 Nov 1;82(9):2823-8 [7693049.001]
  • [Cites] Blood. 1994 Mar 15;83(6):1515-26 [7510144.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):180-91 [7995938.001]
  • [Cites] Exp Dermatol. 1992 Dec;1(5):248-52 [1365326.001]
  • [Cites] J Virol. 1996 Jun;70(6):4038-44 [8648741.001]
  • [Cites] Blood. 1996 Nov 15;88(10):3731-40 [8916937.001]
  • [Cites] J Hum Virol. 1998 May-Jun;1(4):302-5 [10195256.001]
  • [Cites] J Immunol. 2005 May 15;174(10):6477-89 [15879151.001]
  • [Cites] Retrovirology. 2005;2:27 [15854229.001]
  • [Cites] Blood. 2005 Sep 1;106(5):1565-73 [15920010.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6058-68 [16155612.001]
  • [Cites] J Virol. 2005 Nov;79(22):14069-78 [16254341.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Blood. 2006 Jul 1;108(1):141-51 [16543476.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1316-22 [17057712.001]
  • [Cites] J Virol. 2007 Feb;81(4):1690-700 [17121800.001]
  • [Cites] Nat Rev Immunol. 2007 Feb;7(2):118-30 [17259968.001]
  • [RetractionIn] Blood. 2014 Jul 10;124(2):305 [24916510.001]
  • (PMID = 20124219.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR007073-08; United States / NCRR NIH HHS / RR / RR014324-05; United States / NCI NIH HHS / CA / P01 CA100730-07; United States / NCI NIH HHS / CA / R21 CA124595; United States / NCI NIH HHS / CA / CA100730-07S19003; United States / NCRR NIH HHS / RR / T32 RR007073-08; United States / NIAID NIH HHS / AI / P30 AI073961; United States / NCRR NIH HHS / RR / R01 RR014324-05; United States / NCI NIH HHS / CA / CA124595; United States / NCI NIH HHS / CA / P01 CA100730-07S19003; United States / NCI NIH HHS / CA / CA100730-07; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Retracted Publication
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2852366
  •  go-up   go-down


31. Yonekura K, Utsunomiya A, Takatsuka Y, Takeuchi S, Tashiro Y, Kanzaki T, Kanekura T: Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant; 2008 Jun;41(12):1029-35
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Graft-versus-adult T-cell leukemia/lymphoma effect following allogeneic hematopoietic stem cell transplantation.
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has proven effective in adult T-cell leukemia/lymphoma (ATL) patients.
  • To study the graft-versus-ATL (Gv-ATL) effects after allo-HSCT, we analyzed 21 ATL patients who had been treated at our hospital.
  • Of these, 18 had acute-, 2 had lymphoma- and 1 had chronic-type ATL; at allo-HSCT, seven patients were in CR, one was in PR, five had stable disease (SD) and eight had progressive disease (PD).
  • Disease state after allo-HSCT was CR in 14, PR in 3, SD in 1 and PD in 3 patients.
  • Among 15 patients who survived longer than 100 days, ATL relapsed in 10 patients, skin relapsed in 9 patients and 5 had relapsed on the skin alone.
  • After we discontinued immunosuppressant therapy in these 10 patients, 8 manifested GVHD; ATL was ameliorated to CR in 6 patients.
  • Our results demonstrate that relapse of ATL after allo-HSCT tends to develop on skin, and Gv-ATL effects played a critical role in the outcome of allo-HSCT for ATL.
  • [MeSH-major] Graft vs Leukemia Effect. Hematopoietic Stem Cell Transplantation / methods. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Cohort Studies. Disease-Free Survival. Drug Administration Schedule. Female. Graft vs Host Disease / drug therapy. Humans. Immunosuppressive Agents / administration & dosage. Immunosuppressive Agents / adverse effects. Kaplan-Meier Estimate. Male. Middle Aged. Recurrence. Retrospective Studies. Skin Diseases / pathology. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18332910.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


32. Richard V, Nadella MV, Green PL, Lairmore MD, Feuer G, Foley JG, Rosol TJ: Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma. Leukemia; 2005 Jul;19(7):1175-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcriptional regulation of parathyroid hormone-related protein promoter P3 by ETS-1 in adult T-cell leukemia/lymphoma.
  • Parathyroid hormone-related protein (PTHrP) plays a primary role in the development of humoral hypercalcemia of malignancy seen in the majority of adult T-cell leukemia/lymphoma (ATLL) patients with human T-cell lymphotropic virus type-1 (HTLV-1) infection.
  • HTLV-1 Tax has been shown to complex with ETS-1 and SP1 to transactivate the PTHrP P3 promoter.
  • Previously, we established a SCID/bg mouse model of human ATL with RV-ATL cells and showed that PTHrP expression was independent of Tax.
  • In this study, we report an inverse correlation of PTHrP with tax/rex mRNA in multiple HTLV-1-positive cell lines and RV-ATL cells.
  • Stimulation of Jurkat T cells with PMA/ionomycin upregulated the PTHrP P3 promoter by a previously characterized Ets binding site and also induced protein/DNA complex formation identical to that observed in RV-ATL cells.
  • Further, we provide evidence that cotransfection with Ets-1 and constitutively active Mek-1 in HTLV-1-negative transformed T cells with stimulation by PMA/ionomycin not only resulted in a robust induction of PTHrP P3 but also formed a complex with ETS-1/P3 EBS similar to that in ATLL cells.
  • Our data demonstrate that transcriptional regulation of PTHrP in ATLL cells can be controlled by T-cell receptor signaling and the ETS and MAPK ERK pathway in a Tax-independent manner.

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Endocrinology. 2000 May;141(5):1882-92 [10803599.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1583-90 [11080795.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Biol Chem. 2001 Dec 7;276(49):46661-70 [11590145.001]
  • [Cites] Gene. 2003 Jan 16;303:11-34 [12559563.001]
  • [Cites] Int J Oncol. 2003 Apr;22(4):799-805 [12632071.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jun 30;204(1-2):155-68 [12850290.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Biochem J. 2003 Jun 15;372(Pt 3):787-97 [12628005.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1984 Oct;81(19):6207-11 [6091140.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):556-63 [3043221.001]
  • [Cites] Science. 1988 Sep 23;241(4873):1652-5 [2843985.001]
  • [Cites] Gene. 1989 Apr 15;77(1):95-105 [2744490.001]
  • [Cites] J Immunol. 1989 Aug 15;143(4):1283-9 [2545785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Jul;86(14):5620-4 [2787512.001]
  • [Cites] J Endocrinol. 1989 Jul;122(1):219-27 [2788697.001]
  • [Cites] Biochem Biophys Res Commun. 1990 Mar 30;167(3):1134-8 [2322262.001]
  • [Cites] J Virol. 1990 Jun;64(6):2825-32 [2335818.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Mol Endocrinol. 1990 Jun;4(6):851-8 [2233743.001]
  • [Cites] J Biol Chem. 1992 Jul 5;267(19):13623-8 [1618864.001]
  • [Cites] Mol Endocrinol. 1992 Oct;6(10):1642-52 [1280327.001]
  • [Cites] Curr Top Microbiol Immunol. 1992;182:421-4 [1490380.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1017-24 [8427983.001]
  • [Cites] Cancer. 1993 May 1;71(9):2803-6 [8467460.001]
  • [Cites] Mol Endocrinol. 1993 Feb;7(2):273-82 [8469240.001]
  • [Cites] Endocrinology. 1993 Jun;132(6):2551-6 [8099324.001]
  • [Cites] Cancer Res. 1993 Jul 1;53(13):2980-6 [8319205.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16730-6 [8393873.001]
  • [Cites] J Virol. 1993 Oct;67(10):6087-95 [8371355.001]
  • [Cites] Urology. 1994 May;43(5):675-9 [8165768.001]
  • [Cites] J Bone Miner Res. 1994 May;9(5):639-44 [8053392.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Sep 13;91(19):8960-3 [8090753.001]
  • [Cites] Endocrinology. 1995 Apr;136(4):1782-9 [7895691.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4064-75 [7623802.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2257-67 [7662973.001]
  • [Cites] Br J Cancer. 1995 Sep;72(3):702-7 [7669584.001]
  • [Cites] Mol Cell Endocrinol. 1995 Jun;111(2):225-32 [7556886.001]
  • [Cites] Endocrinology. 1995 Dec;136(12):5416-22 [7588290.001]
  • [Cites] J Cell Physiol. 1996 Jan;166(1):1-11 [8557757.001]
  • [Cites] Endocrinology. 1996 Apr;137(4):1349-57 [8625910.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3744-50 [8670878.001]
  • [Cites] J Biol Chem. 1997 Feb 21;272(8):4953-8 [9030555.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13897-902 [9391124.001]
  • [Cites] J Biol Chem. 1998 May 8;273(19):11463-71 [9565558.001]
  • [Cites] J Biol Chem. 1998 Jun 5;273(23):14119-29 [9603911.001]
  • [Cites] Cancer Res. 1999 Dec 1;59(23):6015-22 [10606251.001]
  • [Cites] Mol Cell Endocrinol. 1999 Oct 25;156(1-2):13-23 [10612419.001]
  • (PMID = 15889157.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA077911; United States / NCI NIH HHS / CA / P01 CA100730-069003; United States / NCRR NIH HHS / RR / RR00168; United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / P51 RR000168; United States / NCRR NIH HHS / RR / K26 RR000168; United States / NCI NIH HHS / CA / CA77911; United States / NCI NIH HHS / CA / P01 CA100730-03; None / None / / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-03; United States / NCI NIH HHS / CA / P01 CA100730-01; United States / NCI NIH HHS / CA / CA100730-069003; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ETS1 protein, human; 0 / Ets1 protein, mouse; 0 / Gene Products, rex; 0 / Gene Products, tax; 0 / Parathyroid Hormone-Related Protein; 0 / Proto-Oncogene Protein c-ets-1; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / RNA, Messenger; 0 / Receptors, Antigen, T-Cell; 0 / Transcription Factors; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  • [Other-IDs] NLM/ NIHMS94146; NLM/ PMC2661941
  •  go-up   go-down


33. Miyahara H, Itou H, Sekine A, Taniyama D, Katsui T, Tanaka W, Satou R, Kurihara A, Satou Y, Sakamaki F: [A case of adult T-cell leukemia/lymphoma with primary lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):342-6
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of adult T-cell leukemia/lymphoma with primary lung cancer].
  • The mass was pathologically diagnosed as adult T-cell leukemia/lymphoma (ATLL) because of a high HTLV-1 antibody titer, and radiation therapy was started.
  • Autopsy showed ATLL and extensive lung cancer with multiple metastases.
  • There was invasion of ATLL in systemic lymph nodes, which coincided with invasion of adenocarcinoma.
  • CONCLUSION: We encountered a rare case of ATLL and primary lung cancer.
  • [MeSH-major] Adenocarcinoma / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455967.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


34. Fukushima T, Miyazaki Y, Honda S, Kawano F, Moriuchi Y, Masuda M, Tanosaki R, Utsunomiya A, Uike N, Yoshida S, Okamura J, Tomonaga M: Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia; 2005 May;19(5):829-34
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is a distinct peripheral T-cell neoplasm that is highly resistant to chemotherapy.
  • Several groups, including ours, have reported encouraging results of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for patients with ATLL.
  • To confirm our previous report and to establish the basis for a phase II clinical study, we analyzed 40 allo-HSCT for acute and lymphoma types of ATLL in seven institutions in Japan between 1997 and 2002.
  • The estimated 3-year overall and relapse-free survival, and disease relapse were 45.3, 33.8 and 39.3%, respectively.
  • Among 10 cases with ATLL relapse, five cases achieved CR again: three by the reduction or cessation of immunosuppressive agents, which suggested a graft-versus-ATLL (GvATLL) effect.
  • However, univariate or multivariate analysis did not show any benefit of graft-versus-host disease (GVHD) on the prevention of relapse.
  • These results suggested that allo-HSCT was effective for some patients with aggressive ATLL, and that the GvATLL effect could be achieved even without GVHD.
  • A new phase II trial to test the efficacy of allo-HSCT for ATLL is warranted.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Adult. Analysis of Variance. Female. Graft vs Host Disease / etiology. Graft vs Host Disease / therapy. Humans. Japan / epidemiology. Male. Middle Aged. Reproducibility of Results. Retrospective Studies. Survival Analysis. Time Factors. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15744352.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


35. Bazarbachi A, Plumelle Y, Carlos Ramos J, Tortevoye P, Otrock Z, Taylor G, Gessain A, Harrington W, Panelatti G, Hermine O: Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes. J Clin Oncol; 2010 Sep 20;28(27):4177-83
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia/lymphoma showing improved survival in the leukemic subtypes.
  • PURPOSE: Human T-cell lymphotropic virus type-I-associated adult T-cell leukemia/lymphoma (ATL) is an aggressive, chemotherapy-resistant malignancy.
  • Multiple small studies using zidovudine (AZT) and interferon-alfa (IFN-α) have shown response in patients with ATL.
  • PATIENTS AND METHODS: We report a meta-analysis of antiviral therapy of ATL.
  • Medical records of 254 patients with ATL who were treated in the United States, the United Kingdom, Martinique, and continental France were individually reviewed.
  • RESULTS: According to Shimoyama classification, there were 116 patients with acute ATL, 18 patients with chronic ATL, 11 patients with smoldering ATL, and 100 patients with ATL lymphoma.
  • Patients with acute, chronic, and smoldering ATL significantly benefited from first-line antiviral therapy, whereas patients with ATL lymphoma experienced a better outcome with chemotherapy.
  • In acute ATL, achievement of complete remission with antiviral therapy resulted in 82% 5-year survival.
  • Antiviral therapy in chronic and smoldering ATL resulted in 100% 5-year survival.
  • Multivariate analysis confirmed that first-line antiviral therapy significantly improves overall survival of patients with ATL (hazard ratio, 0.47; 95% CI, 0.27 to 0.83; P = .021).
  • CONCLUSION: These results confirm the high efficacy of AZT and IFN, which should now be considered the gold standard first-line therapy in leukemic subtypes of ATL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Survivors
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antiviral Agents / administration & dosage. Chi-Square Distribution. Female. Great Britain. Humans. Interferon-alpha / administration & dosage. Kaplan-Meier Estimate. Male. Martinique. Middle Aged. Proportional Hazards Models. Retrospective Studies. Risk Assessment. Risk Factors. Time Factors. Treatment Outcome. United States. Young Adult. Zidovudine / administration & dosage

  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 Dec 20;28(36):e765; author reply e766 [20921454.001]
  • (PMID = 20585095.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


36. Raza S, Naik S, Kancharla VP, Tafera F, Kalavar MR: Dual-Positive (CD4+/CD8+) Acute Adult T-Cell Leukemia/Lymphoma Associated with Complex Karyotype and Refractory Hypercalcemia: Case Report and Literature Review. Case Rep Oncol; 2010 Sep;3(3):489-94

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual-Positive (CD4+/CD8+) Acute Adult T-Cell Leukemia/Lymphoma Associated with Complex Karyotype and Refractory Hypercalcemia: Case Report and Literature Review.
  • We describe a rare case of adult T-cell leukemia characterized by an expansion of CD4+ CD8+ double-positive lymphocytes associated with human T-lymphotropic virus type 1 (HTLV-1) and a complex karyotype in a 43-year-old Caribbean male who was initially admitted to our hospital with significant lethargy, visual disturbances, dysphagia, right facial palsy and numbness in both feet for 3 days.
  • Bone marrow and CSF flow cytometries revealed abnormal monoclonal expansion of T cells positive for CD4, CD5, CD8 and CD25 but negative for CD7, CD20, CD56, CD68 and terminal deoxynucleotidyl transferase.
  • The polymerase chain reaction analysis showed a distinct band of the T-cell receptor γ gene, revealing T-cell clonal integration of the proviral DNA of HTLV-1, thus confirming the diagnosis of acute adult T-cell leukemia/lymphoma.
  • Although patients with a rare mixed CD4+ CD8+ immunophenotype usually present with an aggressive clinical course and have a poor prognosis, our patient was able to survive for 2.5 years.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1999 Mar 31;81(1):1-5 [10077143.001]
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):395-400 [7812198.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3612-20 [11369658.001]
  • [Cites] Blood. 2001 Jun 15;97(12):3875-81 [11389029.001]
  • [Cites] J R Soc Med. 2003 Mar;96(3):126-7 [12612113.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):527-31 [14657765.001]
  • [Cites] Leuk Res. 1992;16(5):435-41 [1625468.001]
  • [Cites] J Clin Invest. 2006 Apr;116(4):974-83 [16585963.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Am J Clin Pathol. 2007 Nov;128(5):875-82 [17951212.001]
  • [Cites] Leuk Res. 1991;15(7):619-25 [1861543.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):745-8 [1911223.001]
  • [Cites] J Acquir Immune Defic Syndr. 1990;3(11):1096-101 [2213510.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Leuk Res. 1985;9(11):1353-9 [2867255.001]
  • [Cites] Leuk Res. 1987;11(7):665-8 [2886703.001]
  • [Cites] Proc Natl Acad Sci U S A. 1988 Dec;85(23):9171-5 [3194418.001]
  • [Cites] Int J Hematol. 1997 Oct;66(3):257-78 [9401272.001]
  • [Cites] J Biol Chem. 1993 Jan 15;268(2):1174-9 [8380405.001]
  • [Cites] Int J Dermatol. 2006 Oct;45(10):1193-5 [17040438.001]
  • [Cites] J Natl Cancer Inst. 1985 Feb;74(2):357-69 [2983135.001]
  • [Cites] Nature. 1988 Oct 13;335(6191):642-4 [3262830.001]
  • [Cites] Leuk Res. 2000 Apr;24(4):353-8 [10713333.001]
  • (PMID = 21611103.001).
  • [ISSN] 1662-6575
  • [Journal-full-title] Case reports in oncology
  • [ISO-abbreviation] Case Rep Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Other-IDs] NLM/ PMC3100272
  • [Keywords] NOTNLM ; Acute T-cell leukemia / Cyclophosphamide / Doxorubicin / Etoposide / Human T-lymphotropic virus type 1 (HTLV-1) / Prednisone / Vincristine
  •  go-up   go-down


37. Ghez D, Renand A, Lepelletier Y, Sibon D, Suarez F, Rubio MT, Delarue R, Buzyn A, Beljord K, Tanaka Y, Varet B, Hermine O: Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation. J Clin Virol; 2009 Dec;46(4):378-80
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tax unleashed: fulminant Tax-positive Adult T-cell Leukemia/Lymphoma after failed allogeneic stem cell transplantation.
  • The human retrovirus HTLV-1 causes Adult T-cell Leukemia/Lymphoma (ATLL), a malignant lymphoproliferative disease of CD4+ T cells of dismal prognosis, in 3-5% of the 20 million infected individuals (Proietti et al.(1) and Bazarbachi et al.(2)).
  • Infection with HTLV-1 represents a prototypical model of virus-mediated oncogenesis by virtue of the viral transactivator Tax, a potent oncogenic protein that exerts pleiotropic effects through its ability to deregulate the transcription of various cellular genes and signal transduction pathways and inhibit DNA repair enzymes, which are critical for T-cell homeostasis and genetic stability (Matsuoka and Jeang(3)) (et Boxus Retrovirology 2009).
  • Tax protein expression is undetectable using conventional methods in freshly harvested ATLL cells and in non-malignant infected CD4+ T cells (Furukawa et al.(4)) but is up regulated after only a few hours of culture in vitro (Hanon et al.(5)).
  • These observations strongly suggest that a host-derived mechanism is able to either actively repress the transcription of viral proteins in vivo or refrain the emergence of Tax-expressing cells, which would have a growth advantage.
  • We report herein a unique case of CD4+ T-cell leukemia highly expressing Tax following rejection of an allogenic peripheral blood stem cell graft for an HTLV-1 associated lymphoma.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. Gene Products, tax / metabolism. HTLV-I Infections / immunology. Human T-lymphotropic virus 1 / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology
  • [MeSH-minor] Adult. Hematopoietic Stem Cell Transplantation. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19836302.001).
  • [ISSN] 1873-5967
  • [Journal-full-title] Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
  • [ISO-abbreviation] J. Clin. Virol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Gene Products, tax
  •  go-up   go-down


38. Nakahata S, Yamazaki S, Nakauchi H, Morishita K: Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene; 2010 Jul 22;29(29):4157-69

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma.
  • Zinc-finger E-box binding homeobox 1 (ZEB1) is a candidate tumor-suppressor gene in adult T-cell leukemia/lymphoma (ATLL).
  • In addition to downregulation of ZEB1 mRNA, we found overexpression of inhibitory Smad, Smad7, in resistance of ATLL cells to growth suppression by TGF-beta1.
  • A protein complex of Smad7 and histone deacetylase constantly bound to the promoter region of TGF-beta1 responsive genes with the Smad-responsive element (SRE) to inhibit TGF-beta1 signaling; however, ectopic expression of ZEB1 reactivated TGF-beta1 signaling by binding to Smad7 and recruiting the Smad3/p300 histone acetyltransferase complex to the promoter after TGF-beta1 stimulation in ATLL.
  • Conversely, because ZEB1 mRNA was detected in the late stages of T-cell development, we used CTLL2 cells with ZEB1 expression, a murine peripheral T-cell lymphoma, and found that a complex of Smad3, Smad7 and ZEB1 was bound to the SRE of the p21(CDKN1A) promoter after the induction of Smad7 by TGF-beta1 treatment.
  • Altogether, these results suggest that both ZEB1 downregulation and Smad7 overexpression contribute to resistance to TGF-beta1-mediated growth suppression in ATLL.
  • [MeSH-major] Homeodomain Proteins / physiology. Leukemia-Lymphoma, Adult T-Cell / pathology. Smad7 Protein / physiology. Transcription Factors / physiology. Transforming Growth Factor beta1 / metabolism
  • [MeSH-minor] Cell Line, Tumor. Cell Proliferation. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Down-Regulation. Humans. Plasminogen Activator Inhibitor 1 / genetics. Promoter Regions, Genetic. RNA, Messenger / analysis. Signal Transduction. Smad3 Protein / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Oncogene. 2011 Jun 23;30(25):2900
  • (PMID = 20514018.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Homeodomain Proteins; 0 / Plasminogen Activator Inhibitor 1; 0 / RNA, Messenger; 0 / SMAD3 protein, human; 0 / SMAD7 protein, human; 0 / Smad3 Protein; 0 / Smad7 Protein; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / ZEB1 protein, human
  •  go-up   go-down


39. Olivo RA, Martins FF, Soares S, Moraes-Souza H: Adult T-cell leukemia/lymphoma: report of two cases. Rev Soc Bras Med Trop; 2008 May-Jun;41(3):288-92

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma: report of two cases.
  • Adult T-cell leukemia/lymphoma is a lymphoproliferative disorder of mature T lymphocytes associated with infection with human T-cell lymphotrophic virus type I (HTLV-I).
  • Adult T-cell leukemia/lymphoma is characterized by clinical and laboratory polymorphism that allows it to be classified into four distinct subgroups: smoldering, chronic, acute and lymphomatous types.
  • We present here two cases of adult T-cell leukemia/lymphoma, respectively in the acute and lymphomatous forms of the disease.
  • Case 1 was a 35-year-old woman who presented abdominal distension accompanied by hepatosplenomegaly, adenomegaly, skin lesions, positivity for anti-HTLV-I antibodies and leukocytosis with the presence of flower cells.
  • Case 2 was a 38-year-old man who was admitted with generalized lymphadenomegaly, positivity for anti-HTLV-I antibodies, hypercalcemia and osteolytic lesions.
  • In this paper, we correlate the clinical-laboratory findings of these two cases with data in the literature.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Fatal Outcome. Female. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18719810.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


40. Faris M: Potential for molecular targeted therapy for adult T-cell leukemia/lymphoma. Int Rev Immunol; 2008 Jan-Apr;27(1-2):71-8
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential for molecular targeted therapy for adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma is an aggressive lymphoproliferative disorder of CD4+ T lymphocytes associated with human T-cell leukemia virus type 1 (HTLV-I) infection.
  • Approximately 5% of infected people will develop an aggressive form of ATL, characterized by high circulating cell count, skin and organ infiltration and expression of cytokine, chemokine and survival genes.
  • The available therapies for ATL have minimal efficacy, with few responders and poor survival.
  • Recent advances have led to the identification of key molecules and cellular pathways involved in HTLV-1 mediated cellular transformation and tumor progression.
  • We describe within a few key elements that contribute to neoplastic development of ATL, in addition to interesting molecular drug targets that may lead to more effective therapeutic strategies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Basic-Leucine Zipper Transcription Factors / metabolism. CD4-Positive T-Lymphocytes / immunology. CD4-Positive T-Lymphocytes / metabolism. CD4-Positive T-Lymphocytes / virology. Cytokines / immunology. Cytokines / metabolism. Gene Products, tax / metabolism. HTLV-I Infections / drug therapy. HTLV-I Infections / immunology. HTLV-I Infections / virology. Human T-lymphotropic virus 1 / drug effects. Human T-lymphotropic virus 1 / metabolism. Humans. Viral Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300056.001).
  • [ISSN] 0883-0185
  • [Journal-full-title] International reviews of immunology
  • [ISO-abbreviation] Int. Rev. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Basic-Leucine Zipper Transcription Factors; 0 / Cytokines; 0 / Gene Products, tax; 0 / HBZ protein, human T-cell leukemia virus type I; 0 / Viral Proteins
  • [Number-of-references] 28
  •  go-up   go-down


41. Tawara M, Hogerzeil SJ, Yamada Y, Takasaki Y, Soda H, Hasegawa H, Murata K, Ikeda S, Imaizumi Y, Sugahara K, Tsuruda K, Tsukasaki K, Tomonaga M, Hirakata Y, Kamihira S: Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma. Cancer Lett; 2006 Mar 28;234(2):249-55
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of p53 aberration on the progression of Adult T-cell Leukemia/Lymphoma.
  • Based on statistical analysis of its age-dependent occurrence, a multi-step carcinogenesis model has been proposed for Adult T-cell Leukemia/Lymphoma (ATLL).
  • We have previously reported that the deletion of the p16 gene is a key event in ATLL progression.
  • In the current study, we report for the first time that the aberrations of p16 and p53 are mutually exclusive in ATLL and either of the two events is sufficient for the ATLL progression.
  • [MeSH-major] Biomarkers, Tumor / genetics. Chromosome Aberrations. Genes, p16. Genes, p53. Leukemia, T-Cell / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Humans. Male. Polymorphism, Single-Stranded Conformational. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896902.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


42. Yasunami T, Wang YH, Tsuji K, Takanashi M, Yamada Y, Motoji T: Multidrug resistance protein expression of adult T-cell leukemia/lymphoma. Leuk Res; 2007 Apr;31(4):465-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance protein expression of adult T-cell leukemia/lymphoma.
  • In adult T-cell leukemia/lymphoma (ATL), it is difficult to achieve remission and the reason for the resistance to chemotherapeutic agents may be linked to the presence of multidrug resistance (MDR) proteins.
  • Lung resistance-related protein (LRP), multidrug resistance-associated protein and P-glycoprotein are three MDR proteins which we examined in ATL cells using multiparametric flow cytometry and real-time RT-PCR.
  • This indicates LRP may be contributing to drug resistance in ATL patients, and the suppression of LRP function could be a new strategy for ATL treatment.
  • [MeSH-major] Drug Resistance, Multiple. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Leukemia-Lymphoma, Adult T-Cell / metabolism. Multidrug Resistance-Associated Proteins / metabolism. P-Glycoprotein / metabolism. Vault Ribonucleoprotein Particles / metabolism
  • [MeSH-minor] Adult. Aged. Antibiotics, Antineoplastic / pharmacology. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Flow Cytometry. Humans. Male. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17134750.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Multidrug Resistance-Associated Proteins; 0 / P-Glycoprotein; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; 0 / multidrug resistance-associated protein 1; 80168379AG / Doxorubicin
  •  go-up   go-down


43. Shtalrid M, Shvidel L, Korenfeld R, Duek A, Landau Z, Berrebi A: HTLV-1 associated adult T-cell leukemia/lymphoma in Israel: report of two patients of Romanian origin. Haematologica; 2005 Mar;90(3):ECR13

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1 associated adult T-cell leukemia/lymphoma in Israel: report of two patients of Romanian origin.
  • Human T-lymphotropic virus type 1 (HTLV-1) was the first human oncovirus isolated by Gallo et al. in 1980 and established as an etiological agent for adult T-cell leukemia/ lymphoma (ATL).
  • Although more than 15 million individuals are infected by HTLV-1 through the world, the spread of the virus is highly endemic.
  • The HTLV-1 infection is prevailing in southwestern Japan, inter-tropical Africa, Central and South America.
  • In Kyushu district, Japan, the seroprevalence reaches >30% in the adult population.
  • In the US, Europe and the Middle East the HTLV-1 infection is very rare, and cases of ATL have been reported sporadically.
  • We describe here acute ATL in two patients of Jewish- Romanian origin.
  • The epidemiological anamnesis and screening indicate that both patients acquired the HTLV-1 from their mothers leaving in Romania.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / transmission
  • [MeSH-minor] Family Health. Humans. Infectious Disease Transmission, Vertical. Israel / epidemiology. Jews. Romania / ethnology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15753054.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


44. Hokama A, Tomoyose T, Yamamoto Y, Watanabe T, Hirata T, Kinjo F, Kato S, Ohshima K, Uezato H, Takasu N, Fujita J: Adult T-cell leukemia/lymphoma presenting multiple lymphomatous polyposis. World J Gastroenterol; 2008 Nov 14;14(42):6584-8
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma presenting multiple lymphomatous polyposis.
  • Multiple lymphomatous polyposis (MLP) is an unusual form of non-Hodgkin's lymphoma characterized by polyps throughout the gastrointestinal tract.
  • It has been reported that most MLP are observed in cases with mantle cell lymphoma of B-cell type.
  • We herein present a case of a 66-year-old man with adult T-cell leukemia/lymphoma (ATLL).
  • Colonoscopy revealed MLP throughout the colon and histopathological findings of ATLL cell infiltration.
  • The literature of manifestations of colonic involvement of ATLL is reviewed and the importance of endoscopic evaluation to differentiate ATLL intestinal lesions from opportunistic infectious enterocolitis is discussed.
  • [MeSH-major] Colonic Polyps / etiology. Intestinal Polyposis / etiology. Leukemia-Lymphoma, Adult T-Cell / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Colonoscopy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1993 Oct;11(3-4):281-6 [8260899.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1768-73 [18350608.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):261 [14745401.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):805-8 [14997894.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):788-92 [15338374.001]
  • [Cites] Histopathology. 1984 Jul;8(4):641-56 [6479906.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):824-8 [3257406.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):708-16 [8431850.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):3042-50 [7954267.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):396-402 [8697382.001]
  • [Cites] Endoscopy. 1995 Nov;27(9):700-3 [8903987.001]
  • [Cites] J Gastroenterol. 1997 Aug;32(4):553-7 [9250907.001]
  • [Cites] J Clin Immunol. 1999 May;19(3):186-93 [10404404.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Gastrointest Endosc. 2004 Dec;60(6):983-4 [15605016.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Trop Med Hyg. 2006 Feb;74(2):246-9 [16474078.001]
  • [Cites] Gut. 2006 Nov;55(11):1574, 1591 [17047108.001]
  • [Cites] Lancet Infect Dis. 2007 Apr;7(4):266-81 [17376384.001]
  • [Cites] Gastrointest Endosc. 2007 Apr;65(4):712-3 [17383471.001]
  • [Cites] Cancer Sci. 2007 Jun;98(6):772-8 [17388788.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):241-6 [11500618.001]
  • (PMID = 19030219.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 24
  • [Other-IDs] NLM/ PMC2773353
  •  go-up   go-down


45. Oshiro A, Tagawa H, Ohshima K, Karube K, Uike N, Tashiro Y, Utsunomiya A, Masuda M, Takasu N, Nakamura S, Morishima Y, Seto M: Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma. Blood; 2006 Jun 1;107(11):4500-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of subtype-specific genomic alterations in aggressive adult T-cell leukemia/lymphoma.
  • Aggressive adult T-cell leukemia/lymphoma (ATLL) such as acute and lymphoma types are fatal diseases with poor prognosis.
  • We performed array-based comparative genomic hybridization for 17 acute and 49 lymphoma cases as well as real-time quantitative polymerase chain reaction (PCR) to identify the target genes of recurrently amplified regions.
  • Comparison of the genome profiles of acute and lymphoma types revealed that the lymphoma type had significantly more frequent gains at 1q, 2p, 4q, 7p, and 7q, and losses of 10p, 13q, 16q, and 18p, whereas the acute type showed a gain of 3/3p.
  • Of the recurrent high-level amplifications found at 1p36, 6p25, 7p22, 7q, and 14q32 in the lymphoma type, we were able to demonstrate that CARMA1 is a possible target gene of the 7p22 amplification for the lymphoma type but not for the acute type.
  • Furthermore, we found BCL11B overexpression in the acute type regardless of the 14q32 gain/amplification, but no or low expression of the gene in the lymphoma type.
  • These results suggest that acute and lymphoma types are genomically distinct subtypes, and thus may develop tumors via distinct genetic pathways.
  • [MeSH-major] Gene Amplification. Genome, Human. Leukemia-Lymphoma, Adult T-Cell / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Apoptosis Regulatory Proteins / genetics. CARD Signaling Adaptor Proteins. Chromosomes. DNA-Binding Proteins / genetics. Female. Gene Dosage. Gene Expression Regulation, Neoplastic. Guanylate Cyclase / genetics. Humans. Lymphoma / genetics. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction. Repressor Proteins / genetics. Tumor Suppressor Proteins / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16484591.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / BCL11B protein, human; 0 / CARD Signaling Adaptor Proteins; 0 / DNA-Binding Proteins; 0 / Repressor Proteins; 0 / Tumor Suppressor Proteins; EC 4.6.1.2 / CARD11 protein, human; EC 4.6.1.2 / Guanylate Cyclase
  •  go-up   go-down


46. Owatari S, Otsuka M, Uozumi K, Takeshita T, Hanada S: Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma. Int J Hematol; 2007 Jan;85(1):32-5
Hazardous Substances Data Bank. PODOFILOX .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of secondary acute myeloid leukemia accompanying adult T-cell leukemia/lymphoma.
  • We identified 2 cases of secondary acute myeloid leukemia (AML) following adult T-cell leukemia/lymphoma (ATL) in patients who had previously received chemotherapy.
  • Both cases were thought to represent therapy-related AML because the patients had previously received combination chemotherapy including epipodophyllotoxin, anthracycline, and alkylating agents for the ATL.
  • In our hospital, only these 2 cases of secondary AML accompanying ATL were identified among 90 cases of acute- or lymphoma-type ATL diagnosed from October 1999 to July 2006.
  • The frequency of coexisting AML and ATL is lower than that reported for acute leukemia coexisting with other lymphoid malignancies.
  • The low frequency of secondary leukemia with ATL may be associated with the short survival times of ATL patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid / chemically induced. Leukemia-Lymphoma, Adult T-Cell / complications. Neoplasms, Second Primary / chemically induced
  • [MeSH-minor] Acute Disease. Alkylating Agents / therapeutic use. Anthracyclines / therapeutic use. Chromosome Aberrations. Female. Humans. Leukemia, Myeloid, Acute / chemically induced. Leukemia, Myelomonocytic, Acute / chemically induced. Male. Middle Aged. Podophyllotoxin / therapeutic use

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17261499.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Alkylating Agents; 0 / Anthracyclines; L36H50F353 / Podophyllotoxin
  •  go-up   go-down


47. Hidaka T, Nakahata S, Hatakeyama K, Hamasaki M, Yamashita K, Kohno T, Arai Y, Taki T, Nishida K, Okayama A, Asada Y, Yamaguchi R, Tsubouchi H, Yokota J, Taniwaki M, Higashi Y, Morishita K: Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma. Blood; 2008 Jul 15;112(2):383-93
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of TCF8 is involved in the leukemogenesis of adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by latent human T-lymphotropic virus-1 (HTLV-1) infection.
  • To clarify the molecular mechanism underlying leukemogenesis after viral infection, we precisely mapped 605 chromosomal breakpoints in 61 ATLL cases by spectral karyotyping and identified frequent chromosomal breakpoints in 10p11, 14q11, and 14q32.
  • Single nucleotide polymorphism (SNP) array-comparative genomic hybridization (CGH), genetic, and expression analyses of the genes mapped within a common breakpoint cluster region in 10p11.2 revealed that in ATLL cells, transcription factor 8 (TCF8) was frequently disrupted by several mechanisms, including mainly epigenetic dysregulation.
  • TCF8 mutant mice frequently developed invasive CD4(+) T-cell lymphomas in the thymus or in ascitic fluid in vivo.
  • Down-regulation of TCF8 expression in ATLL cells in vitro was associated with resistance to transforming growth factor beta1 (TGF-beta1), a well-known characteristic of ATLL cells, suggesting that escape from TGF-beta1-mediated growth inhibition is important in the pathogenesis of ATLL.
  • These findings indicate that TCF8 has a tumor suppressor role in ATLL.
  • [MeSH-major] Homeodomain Proteins / physiology. Leukemia-Lymphoma, Adult T-Cell / etiology. Transcription Factors / physiology. Transforming Growth Factor beta1 / physiology
  • [MeSH-minor] Animals. Chromosome Breakage. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 14. Down-Regulation / genetics. Humans. Karyotyping. Mice. Tumor Cells, Cultured

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18467597.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Transcription Factors; 0 / Transforming Growth Factor beta1; 0 / ZEB1 protein, human
  •  go-up   go-down


48. Yamada Y, Kamihira S: Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma. Leuk Lymphoma; 2005 Nov;46(11):1553-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of tumor suppressor genes and the progression of adult T-cell leukemia-lymphoma.
  • Almost three decades have passed since adult T-cell leukemia-lymphoma (ATLL) was proposed as a new disease entity.
  • During this period, its causative agent, human T-cell leukemia virus type-1 (HTLV-1), was found and a crucial role of the viral product Tax in the development of ATLL was disclosed.
  • However, the long latent period after infection with HTLV-1 indicates the need for additional factors for full-blown ATLL, most of which are supposed to be provided by somatic mutations of cellular genes.
  • Recent progress in cell-cycle research has revealed that the uncontrolled and superior proliferative activity of malignant cells is mainly caused by the breakdown of cell-cycle regulation and that most malignancies carry aberrations in p16-pRB and/or p53 pathways.
  • ATLL is not an exception, despite the consistent association of HTLV-1 in primary leukemia cells, and accumulating evidence indicates that the breakdown of these pathways is indeed involved in the leukemogenesis of ATLL, especially in its later steps, which serve as the key events for promotion of indolent ATLL to aggressive ATLL.
  • [MeSH-major] Gene Silencing. Genes, Tumor Suppressor. Leukemia-Lymphoma, Adult T-Cell / etiology
  • [MeSH-minor] Disease Progression. Genes, cdc. Humans

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236609.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 47
  •  go-up   go-down


49. Ishitsuka K, Tamura K: Treatment of adult T-cell leukemia/lymphoma: past, present, and future. Eur J Haematol; 2008 Mar;80(3):185-96
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of adult T-cell leukemia/lymphoma: past, present, and future.
  • Adult T-cell leukemia/lymphoma (ATLL) is a peripheral T-cell malignancy caused by human T-cell lymphotrophic virus type I.
  • Clinical manifestations of ATLL range from smoldering to chronic, lymphoma and acute.
  • Patients with acute and lymphoma type ATLL require therapeutic intervention.
  • Conventional chemotherapeutic regimens used against other malignant lymphoma have been administered to ATLL patients, but the therapeutic outcomes of acute and lymphoma type ATLL remain very poor.
  • Promising results of allogeneic stem cell transplantation (SCT) for ATLL patients have recently been reported and the treatment outcome might be improved for some ATLL patients.
  • Besides conventional chemotherapy and SCT, interferon, zidovudine, arsenic trioxide, targeted therapy against surface molecule on ATLL cells, retinoid derivatives, and bortezomib have been administered to ATLL patients in pilot or phase I/II studies.
  • Further studies are required to confirm the clinical benefits of these novel therapeutics.
  • This article reviews the current status and future directions of ATLL treatment.
  • [MeSH-major] Human T-lymphotropic virus 1. Leukemia-Lymphoma, Adult T-Cell / therapy
  • [MeSH-minor] Clinical Trials as Topic / trends. Forecasting. France / epidemiology. Humans. Japan / epidemiology. Prospective Studies. Stem Cell Transplantation / trends

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18081707.001).
  • [ISSN] 1600-0609
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 157
  •  go-up   go-down


50. Koga Y, Iwanaga M, Soda M, Inokuchi N, Sasaki D, Hasegawa H, Yanagihara K, Yamaguchi K, Kamihira S, Yamada Y: Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan. J Med Virol; 2010 Apr;82(4):668-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in HTLV-1 prevalence and incidence of adult T-cell leukemia/lymphoma in Nagasaki, Japan.
  • Most previous studies aimed at estimating the number of human T-cell leukemia virus type-1 (HTLV-1) carriers in endemic areas have been based on seroprevalence rates in blood donors; however, this may result in underestimation because of the healthy donor effect.
  • In the present study, the number of HTLV-1 carriers in Nagasaki City was estimated based on the seroprevalence rates in a hospital-based population from Nagasaki University Hospital.
  • In accordance with previous reports, seroprevalence of HTLV-1 was higher in females, and year of birth-specific seroprevalence showed a significant annual decline in both genders (P for trend: <0.0001).
  • The estimated number of HTLV-1 carriers in Nagasaki City was 36,983.
  • The incidence of adult T-cell leukemia/lymphoma (ATLL) among HTLV-1 carriers was estimated using data from the Nagasaki Prefectural Cancer Registry.
  • The estimated annual incidence of ATLL was 61 per 100,000 HTLV-1 carriers, and the crude lifetime risk of the development was 7.29% for males and 3.78% for females.
  • There is a large pool of HTLV-1 carriers aged over 70 years, and a continuing development of cases of ATLL among the elderly is therefore expected.
  • [MeSH-major] HTLV-I Infections / complications. HTLV-I Infections / epidemiology. Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / epidemiology. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carrier State / epidemiology. Child. Child, Preschool. Female. Hospitals. Humans. Incidence. Infant. Infant, Newborn. Japan. Male. Middle Aged. Seroepidemiologic Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Wiley-Liss, Inc.
  • (PMID = 20166187.001).
  • [ISSN] 1096-9071
  • [Journal-full-title] Journal of medical virology
  • [ISO-abbreviation] J. Med. Virol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Yokote T, Akioka T, Oka S, Hara S, Kobayashi K, Nakajima H, Yamano T, Ikemoto T, Shimizu A, Tsuji M, Hanafusa T: Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol; 2005 Aug;124(2):199-204

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating.
  • Adult T-cell leukemia/lymphoma (ATLL) is a lymphoproliferative neoplasm of helper T lymphocytes caused by human T-cell leukemia virus type-1 (HTLV-1).
  • The disease was first described in Kyushu, in southwestern Japan, and most frequently occurs in endemic areas, such as Japan, the Caribbean basin, West Africa, Brazil, and northern Iran.
  • ATLL is essentially a disease of adults, characterized clinically by generalized lymphadenopathy, hepatosplenomegaly, skin lesions, and hypercalcemia.
  • In the present study, flow cytometric immunophenotyping with CD3 gating was performed on 30 samples from 26 patients who had been given a diagnosis of ATLL.
  • In 14 of the 30 samples, an abnormal CD3(low) T-cell population was distinguishable from the normal T-cell populations by flow cytometric analysis.
  • Herein we report a novel strategy for flow cytometric immunophenotyping of ATLL facilitated by CD3(low) gating.
  • [MeSH-major] Antigens, CD3 / metabolism. Biomarkers, Tumor / analysis. Flow Cytometry. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Antigens, CD4 / metabolism. Antigens, CD7 / metabolism. Antigens, CD8 / metabolism. Humans. Immunohistochemistry. Immunophenotyping. Middle Aged. Retrospective Studies. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16040289.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD7; 0 / Antigens, CD8; 0 / Biomarkers, Tumor
  •  go-up   go-down


52. Yano H, Ishida T, Inagaki A, Ishii T, Kusumoto S, Komatsu H, Iida S, Utsunomiya A, Ueda R: Regulatory T-cell function of adult T-cell leukemia/lymphoma cells. Int J Cancer; 2007 May 1;120(9):2052-7
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regulatory T-cell function of adult T-cell leukemia/lymphoma cells.
  • Adult T-cell leukemia/lymphoma (ATLL) patients are highly immunocompromised, but the underlying mechanism responsible for this state remains obscure.
  • Recent studies demonstrated that FOXP3, which is a master control gene of naturally occurring regulatory T (Treg) cells, is expressed in the tumor cells from a subset of patients with ATLL.
  • Since most ATLL cells express both CD4 and CD25, these tumors might originate from CD4(+)CD25(+)FOXP3(+) Treg cells, based on their phenotypic characteristics.
  • However, whether ATLL cells actually function as Treg cells has not yet been clearly demonstrated.
  • Here, we show that ATLL cells from a subset of patients are not only hypo-responsive to T-cell receptor-mediated activation, but also suppress the proliferation of autologous CD4(+) non-ATLL cells.
  • Furthermore, ATLL cells from this subset of patients secrete only small amounts of IFN-gamma, and suppress IFN-gamma production by autologous CD4(+) non-ATLL cells.
  • These are the first data showing that ATLL cells from a subset of patients function as Treg cells in an autologous setting.
  • The present study provides novel insights into understanding the immunopathogenesis of ATLL, i.e., how HTLV-1-infected cells can survive in the face of host immune responses.
  • It also adds to our understanding of ATLL patients' severely immunocompromised state.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes, Regulatory / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17278106.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00355472
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCR4 protein, human; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / RNA, Messenger; 0 / Receptors, CCR4; 0 / Receptors, Chemokine; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


53. Shimakage M, Inoue N, Ohshima K, Kawahara K, Oka T, Yasui K, Matsumoto K, Inoue H, Watari A, Higashiyama S, Yutsudo M: Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma. Int J Cancer; 2006 Oct 1;119(7):1648-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-regulation of ASY/Nogo transcription associated with progression of adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is an aggressive form of human leukemia/lymphoma.
  • Although this disease is initiated by infection with human T-lymphotropic virus type 1 (HTLV-1), many HTLV-1 carriers survive for a long period without aggressive illness, suggesting that other factors may play roles in the progression of ATLL to an aggressive state.
  • Previously, we have reported that ASY/Nogo mRNA was markedly down-regulated in human small-cell lung carcinomas, whereas it was expressed in normal tissues and other lung carcinomas, such as adenocarcinoma and squamous cell carcinoma.
  • To understand whether or not ASY/Nogo gene is involved in the progression of ATLL, we examined the expression of ASY/Nogo mRNA in smoldering, chronic and aggressive ATLL, and found that the expression level of ASY/Nogo mRNA was markedly reduced in clinically aggressive ATLL.
  • HTLV-1 Tax expression was not affected by the down-regulation of ASY/Nogo mRNA.
  • These results indicate that the ASY/Nogo gene may act as a suppressor against ATLL progression, independent of Tax expression.
  • [MeSH-major] Down-Regulation / genetics. Gene Expression Regulation, Neoplastic / genetics. Intracellular Signaling Peptides and Proteins / genetics. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / pathology. Membrane Proteins / genetics. Myelin Proteins / genetics. Transcription, Genetic / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Female. Gene Products, tax / genetics. Humans. Male. Middle Aged. RNA, Messenger / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16646068.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / Intracellular Signaling Peptides and Proteins; 0 / Membrane Proteins; 0 / Myelin Proteins; 0 / Nogo protein; 0 / RNA, Messenger
  •  go-up   go-down


54. Okada J, Imafuku S, Tsujita J, Moroi Y, Urabe K, Furue M: Case of adult T-cell leukemia/lymphoma manifesting marked purpura. J Dermatol; 2007 Nov;34(11):782-5
MedlinePlus Health Information. consumer health - Skin Pigmentation Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case of adult T-cell leukemia/lymphoma manifesting marked purpura.
  • Antibody to human T-lymphotropic virus type 1 (HTLV-1) was present in the serum and samples from skin lesions revealed HTLV-1 proviral DNA integration, as well as a clonal T-cell receptor Cbeta1 gene rearrangement.
  • We therefore diagnosed this case as adult T-cell leukemia/lymphoma (ATL), and the purpuric lesions as ATL-specific.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Pigmentation Disorders / etiology. Purpura / etiology
  • [MeSH-minor] Blotting, Southern. Female. Gene Rearrangement, beta-Chain T-Cell Antigen Receptor. Humans. Lymphocytes / immunology. Middle Aged. Skin / pathology. Skin / virology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17973821.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


55. Watanabe N, Murakami J, Kameda K, Kato H, Kamisaki Y, Noguchi K, Funada H, Seto H: F-18 FDG-PET imaging in adult T-cell leukemia lymphoma. Clin Nucl Med; 2008 Jun;33(6):423-5
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] F-18 FDG-PET imaging in adult T-cell leukemia lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Leukemia, T-Cell / radionuclide imaging. Liver Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Humans. Lymphatic Metastasis. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18496454.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


56. Uozumi K, Arima N: [Treatment of adult t-cell leukemia * lymphoma]. Nihon Rinsho; 2007 Jan 28;65 Suppl 1:575-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of adult t-cell leukemia * lymphoma].
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474464.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 11
  •  go-up   go-down


57. Tsukasaki K: [International consensus on the management of adult T-cell leukemia-lymphoma]. Rinsho Ketsueki; 2010 Jul;51(7):493-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [International consensus on the management of adult T-cell leukemia-lymphoma].
  • [MeSH-major] International Cooperation. Leukemia-Lymphoma, Adult T-Cell
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Therapy, Combination. Hematopoietic Stem Cell Transplantation. Human T-lymphotropic virus 1. Humans. Interferon-alpha / therapeutic use. Prednisolone / administration & dosage. Prognosis. Transplantation, Homologous. Vincristine / administration & dosage. Zidovudine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20693768.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


58. Hsi ED: T-cell lymphoma in the head and neck? Think about adult T-cell leukemia/lymphoma. Leuk Lymphoma; 2009 Feb;50(2):150-1
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoma in the head and neck? Think about adult T-cell leukemia/lymphoma.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. HTLV-I Infections / complications. HTLV-I Infections / pathology. Human T-lymphotropic virus 1 / physiology. Humans

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Leuk Lymphoma. 2009 Feb;50(2):187-95 [19197730.001]
  • (PMID = 19235010.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Jankipersadsing V, Tauchi T, Ohyashiki K, Tanaka Y, Setoguchi Y, Mukai K: Spontaneous regression of pulmonary infiltration of adult T-cell leukemia/lymphoma. Int J Hematol; 2007 Oct;86(3):207

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous regression of pulmonary infiltration of adult T-cell leukemia/lymphoma.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration / pathology. Lung / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988983.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


60. Mori N: [Molecular targeted therapy in adult T-cell leukemia/lymphoma]. Nihon Rinsho; 2007 Jan 28;65 Suppl 1:709-18

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular targeted therapy in adult T-cell leukemia/lymphoma].
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Antigens, Surface / immunology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Humans. NF-kappa B / antagonists & inhibitors. Phosphatidylinositol 3-Kinases / antagonists & inhibitors. Protein-Tyrosine Kinases / antagonists & inhibitors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474481.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / HSP90 Heat-Shock Proteins; 0 / NF-kappa B; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 30
  •  go-up   go-down


61. Janik JE, Morris JC: Survivin(g) adult T-cell leukemia/lymphoma. Oncology (Williston Park); 2009 Dec;23(14):1256, 1261, 1266
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survivin(g) adult T-cell leukemia/lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Neoplasm / genetics. Hematopoietic Stem Cell Transplantation. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Leukemia-Lymphoma, Adult T-Cell / therapy. Microtubule-Associated Proteins / genetics
  • [MeSH-minor] Adult. Female. Gene Expression Profiling. Humans. Inhibitor of Apoptosis Proteins. Male. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2009 Dec;23(14):1250-6 [20120837.001]
  • (PMID = 20120838.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Comment; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins
  •  go-up   go-down


62. Maeda Y, Yamaguchi T, Miyatake J, Kanamaru A: [Possible therapy with ATRA for adult T-cell leukemia/lymphoma]. Nihon Rinsho; 2007 Jan 28;65 Suppl 1:719-23
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Possible therapy with ATRA for adult T-cell leukemia/lymphoma].
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / drug therapy. Tretinoin / therapeutic use
  • [MeSH-minor] Adult. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17474482.001).
  • [ISSN] 0047-1852
  • [Journal-full-title] Nihon rinsho. Japanese journal of clinical medicine
  • [ISO-abbreviation] Nippon Rinsho
  • [Language] jpn
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  • [Number-of-references] 13
  •  go-up   go-down


63. Tsukasaki K: [Treatment for adult T-cell leukemia-lymphoma]. Gan To Kagaku Ryoho; 2009 May;36(5):756-61
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment for adult T-cell leukemia-lymphoma].
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / surgery. Leukemia-Lymphoma, Adult T-Cell / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19496285.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 4B9XT59T7S / Zidovudine; 9008-11-1 / Interferons
  •  go-up   go-down


64. Ramos JC, Ruiz P Jr, Ratner L, Reis IM, Brites C, Pedroso C, Byrne GE Jr, Toomey NL, Andela V, Harhaj EW, Lossos IS, Harrington WJ Jr: IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma. Blood; 2007 Apr 1;109(7):3060-8
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IRF-4 and c-Rel expression in antiviral-resistant adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is a generally fatal malignancy.
  • Most ATLL patients fare poorly with conventional chemotherapy; however, antiviral therapy with zidovudine (AZT) and interferon alpha (IFN-alpha) has produced long-term clinical remissions.
  • We studied primary ATLL tumors and identified molecular features linked to sensitivity and resistance to antiviral therapy.
  • This finding was independent of the disease form.
  • Elevated expression of the putative c-Rel target, interferon regulatory factor-4 (IRF-4), was observed in 10 (91%) of 11 nonresponders and in all tested patients with c-Rel+ tumors and occurred in the absence of the HTLV-1 oncoprotein Tax.
  • Gene rearrangement studies demonstrated the persistence of circulating T-cell clones in long-term survivors maintained on antiviral therapy.
  • The expression of nuclear c-Rel and IRF-4 occurs in the absence of Tax in primary ATLL and is associated with antiviral resistance.
  • AZT and IFN-alpha is a suppressive rather than a curative regimen, and patients in clinical remission should remain on maintenance therapy indefinitely.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1994 Sep 15;84(6):1942-9 [8080997.001]
  • [Cites] Oncogene. 1994 Nov;9(11):3289-97 [7936653.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1744-8 [7760890.001]
  • [Cites] N Engl J Med. 1995 Jun 29;332(26):1749-51 [7760891.001]
  • [Cites] Genes Dev. 1995 Aug 15;9(16):1965-77 [7649478.001]
  • [Cites] Blood. 1995 Dec 1;86(11):4063-75 [7492762.001]
  • [Cites] Mol Cell Biol. 1996 Apr;16(4):1283-94 [8657101.001]
  • [Cites] Intervirology. 1995;38(3-4):238-46 [8682622.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jun 1;12(2):182-6 [8680890.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):15989-94 [16236719.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(1):41-4 [16247419.001]
  • [Cites] J Pathol. 2006 Apr;208(5):714-23 [16400625.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] Blood. 2006 Aug 1;108(3):1021-9 [16569765.001]
  • [Cites] Blood. 1998 Jan 15;91(2):570-6 [9427711.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3557-61 [9808547.001]
  • [Cites] Genes Dev. 1999 Feb 15;13(4):382-7 [10049353.001]
  • [Cites] Int J Cancer. 2000 Mar 1;85(5):720-5 [10699955.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2084-92 [10706878.001]
  • [Cites] J Exp Med. 2000 Apr 17;191(8):1281-92 [10770796.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6055-60 [10811897.001]
  • [Cites] Blood. 2000 Oct 1;96(7):2537-42 [11001908.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Nov 1;16(16):1613-22 [11080800.001]
  • [Cites] Cancer Lett. 2000 Nov 10;160(1):89-97 [11098089.001]
  • [Cites] Blood. 2001 Feb 1;97(3):744-51 [11157493.001]
  • [Cites] Oncologist. 2001;6(1):34-55 [11161227.001]
  • [Cites] Annu Rev Immunol. 2001;19:475-96 [11244044.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):779-84 [11380470.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3640-50 [8670867.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13 Suppl 1:S179-85 [8797721.001]
  • [Cites] Science. 1997 Jan 24;275(5299):540-3 [8999800.001]
  • [Cites] Nat Genet. 1997 Oct;17(2):226-30 [9326949.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Br J Haematol. 1999 Jun;105(3):743-51 [10354140.001]
  • [Cites] Exp Hematol. 1999 Jul;27(7):1168-75 [10390192.001]
  • [Cites] J Immunol. 1999 Sep 1;163(5):2713-22 [10453013.001]
  • [Cites] Mol Diagn. 1999 Jun;4(2):101-17 [10462626.001]
  • [Cites] Lancet Oncol. 2004 Nov;5(11):664-72 [15522654.001]
  • [Cites] Br J Haematol. 2005 Jan;128(2):253-65 [15638862.001]
  • [Cites] J Cutan Pathol. 2005 Mar;32(3):227-34 [15701085.001]
  • [Cites] Nat Rev Cancer. 2005 Apr;5(4):297-309 [15803156.001]
  • [Cites] Blood. 2005 Jul 1;106(1):235-40 [15790788.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1382-8 [15831528.001]
  • [Cites] Br J Haematol. 2001 Jul;114(1):63-9 [11472346.001]
  • [Cites] Mol Cell Biol. 2001 Oct;21(19):6369-86 [11533227.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7098-103 [11704834.001]
  • [Cites] J Exp Med. 2001 Dec 17;194(12):1861-74 [11748286.001]
  • [Cites] Jpn J Cancer Res. 2001 Dec;92(12):1284-92 [11749693.001]
  • [Cites] J Interferon Cytokine Res. 2002 Jan;22(1):111-20 [11846982.001]
  • [Cites] Oncogene. 2002 Feb 14;21(8):1251-62 [11850845.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1069-85 [12040438.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):685-94 [12079517.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1828-34 [12176906.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):3120-30 [12218129.001]
  • [Cites] Oncogene. 2002 Oct 3;21(44):6751-65 [12360402.001]
  • [Cites] Hematol J. 2002;3(6):276-82 [12522449.001]
  • [Cites] Leuk Lymphoma. 2002 Dec;43(12):2249-55 [12613509.001]
  • [Cites] J Virol. 2003 May;77(9):5286-94 [12692230.001]
  • [Cites] Blood. 2003 May 1;101(9):3681-6 [12511414.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] Hematol J. 2004;5(2):130-4 [15048063.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S21-6 [15202521.001]
  • [Cites] Leuk Lymphoma. 2003;44 Suppl 3:S41-7 [15202524.001]
  • [Cites] J Exp Med. 2004 Jul 19;200(2):247-53 [15249594.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] Haematol Blood Transfus. 1981;26:502-14 [6274766.001]
  • [Cites] J Exp Med. 1985 Dec 1;162(6):2169-74 [2866223.001]
  • [Cites] Blood. 1987 Nov;70(5):1407-11 [2889484.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • (PMID = 17138822.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA070058; United States / NCI NIH HHS / CA / CA-10521; United States / NCI NIH HHS / CA / R01 CA082274; United States / NCI NIH HHS / CA / CA-082274; United States / NCI NIH HHS / CA / U01-CA-070058
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA-Binding Proteins; 0 / HIVEN86A protein, human; 0 / Interferon Regulatory Factors; 0 / Interferon Type I; 0 / NF-kappa B; 0 / Nuclear Proteins; 0 / Recombinant Proteins; 0 / interferon regulatory factor-4; 4B9XT59T7S / Zidovudine
  • [Other-IDs] NLM/ PMC1852214
  •  go-up   go-down


65. Bitar N, Hajj HE, Houmani Z, Sabbah A, Otrock ZK, Mahfouz R, Zaatari G, Bazarbachi A: Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon. Transfusion; 2009 Sep;49(9):1859-64
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma in the Middle East: first report of two cases from Lebanon.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATL) is an aggressive lymphoproliferative disorder caused by human T-cell leukemia virus type I (HTLV-I).
  • HTLV-I is endemic in southern Japan, the Caribbean, Central and South America, certain areas of Africa, and the southeastern United States.
  • CASE REPORTS: In this report, the first two cases of ATL diagnosed in Lebanon are described.
  • The first patient of Lebanese origin presented with acute ATL.
  • The second patient of Romanian origin developed acute ATL in early relapse after autologous transplantation for ATL.
  • Both patients had lymphocytosis, severe hypercalcemia, and CD25+ T-cell immunophenotype on peripheral blood.
  • In both patients, HTLV-I serology was positive by enzyme-linked immunosorbent assay and confirmed by Western blot and HTLV-I oncoprotein Tax expression was documented in the leukemic cells.
  • Upon screening, seven direct family members of the first patient were HTLV-I positive; four of them were regular blood donors.
  • CONCLUSIONS: Screening blood donors for HTLV-I seropositivity is not currently performed in Lebanon.
  • A large screening study in Lebanon is needed to confirm whether South Lebanon is a new endemic region for HTLV-I infection and to recommend mandatory screening of blood donors for HTLV-I infection.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / pathology
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Bone Density Conservation Agents / therapeutic use. Diphosphonates / therapeutic use. Fatal Outcome. Female. Gene Products, tax / blood. Humans. Imidazoles / therapeutic use. Interferon-alpha / therapeutic use. Lebanon. Middle Aged. Zidovudine / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19453978.001).
  • [ISSN] 1537-2995
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Gene Products, tax; 0 / Imidazoles; 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


66. Shu ST, Martin CK, Thudi NK, Dirksen WP, Rosol TJ: Osteolytic bone resorption in adult T-cell leukemia/lymphoma. Leuk Lymphoma; 2010 Apr;51(4):702-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteolytic bone resorption in adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia/lymphoma (ATLL) is caused by human T lymphotropic virus type 1 (HTLV-1).
  • Patients with ATLL frequently develop humoral hypercalcemia of malignancy (HHM) resulting from increased osteoclastic bone resorption.
  • Our goal was to investigate the mechanisms of ATLL-induced osteoclastic bone resorption.
  • Murine calvaria co-cultured with HTLV-1-infected cells directly or conditioned media from cell cultures had increased osteoclast activity that was dependent on RANKL, indicating that factors secreted from ATLL cells had a stimulatory effect on bone resorption.
  • Factors released from resorbing bone stimulated proliferation of HTLV-1-infected T-cells.
  • Parathyroid hormone-related protein (PTHrP) and macrophage inflammatory protein-1alpha (MIP-1alpha), both osteoclast stimulators, were expressed in HTLV-1-infected T-cell lines.
  • Interestingly, when HTLV-1-infected T-cells were co-cultured with pre-osteoblasts, the expression of osteoprotegerin (OPG), an osteoclast inhibitory factor, was significantly down-regulated in the pre-osteoblasts.
  • When OPG was added into the ex vivo osteoclastogenesis assay induced by HTLV-1-infected T-cells, osteoclastogenesis was strongly inhibited.
  • In addition, HTLV-1-infected T-cells inhibited expression of early osteoblast genes and induced late genes.
  • These regulators will serve as future therapeutic targets for the treatments of HHM in ATLL.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Mar 1;164(5):2718-27 [10679113.001]
  • [Cites] Endocrine. 2009 Feb;35(1):47-56 [18987998.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3349-53 [11369623.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36241-50 [11451955.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36703-10 [11481336.001]
  • [Cites] Rev Endocr Metab Disord. 2000 Nov;1(4):253-63 [11706739.001]
  • [Cites] J Cell Biochem. 2001;84(1):1-11 [11746511.001]
  • [Cites] J Clin Invest. 2001 Dec;108(12):1833-41 [11748267.001]
  • [Cites] Blood. 2002 Jan 15;99(2):634-40 [11781248.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1341-9 [11830485.001]
  • [Cites] Cancer Detect Prev. 2002;26(3):222-8 [12269770.001]
  • [Cites] Blood. 2002 Dec 1;100(12):4129-38 [12393612.001]
  • [Cites] Mol Cell Endocrinol. 2003 Jan 31;199(1-2):165-77 [12581888.001]
  • [Cites] J Virol. 2003 May;77(9):5286-94 [12692230.001]
  • [Cites] Ann N Y Acad Sci. 2003 May;995:109-16 [12814943.001]
  • [Cites] Blood. 2003 Jul 1;102(1):311-9 [12649140.001]
  • [Cites] Clin Chem. 2003 Aug;49(8):1398-402 [12881458.001]
  • [Cites] Oncogene. 2004 Jan 22;23(3):845-51 [14647437.001]
  • [Cites] Neuropathology. 2004 Jun;24(2):131-5 [15139590.001]
  • [Cites] Crit Rev Oncol Hematol. 2004 May;50(2):87-100 [15157658.001]
  • [Cites] J Bone Miner Res. 2004 Jul;19(7):1105-11 [15176993.001]
  • [Cites] Blood. 2004 Aug 1;104(3):802-9 [15090453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(12):4473-5 [1693772.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] J Pathol. 1995 Feb;175(2):227-36 [7738719.001]
  • [Cites] Mol Cell Biol. 1995 Aug;15(8):4064-75 [7623802.001]
  • [Cites] Miner Electrolyte Metab. 1995;21(1-3):166-70 [7565442.001]
  • [Cites] Neurology. 1998 Jun;50(6):1920 [9633766.001]
  • [Cites] Endocrinology. 1999 Oct;140(10):4382-9 [10499489.001]
  • [Cites] Clin Breast Cancer. 2005 Feb;5 Suppl(2):S46-53 [15807924.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2005;15(2):115-32 [16022632.001]
  • [Cites] Calcif Tissue Int. 2005 May;76(5):326-35 [15868281.001]
  • [Cites] Leukemia. 2005 Jul;19(7):1175-83 [15889157.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6109-15 [16144909.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Clin Exp Immunol. 2005 Oct;142(1):12-20 [16178851.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2006 Jan;26(1):200-5 [16254204.001]
  • [Cites] Br J Haematol. 2006 May;133(3):301-4 [16643432.001]
  • [Cites] Curr Opin Rheumatol. 2006 Jul;18(4):396-404 [16763461.001]
  • [Cites] Cancer Metastasis Rev. 2006 Dec;25(4):559-71 [17165129.001]
  • [Cites] Leukemia. 2007 Aug;21(8):1752-62 [17554373.001]
  • [Cites] Eur Urol. 2007 Sep;52(3):791-7 [17207914.001]
  • [Cites] Mol Cancer Ther. 2007 Oct;6(10):2609-17 [17938257.001]
  • [Cites] Cell Metab. 2008 Aug;8(2):132-45 [18680714.001]
  • [Cites] Blood. 2000 Jul 15;96(2):671-5 [10887133.001]
  • (PMID = 20214446.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA100730; United States / NCRR NIH HHS / RR / T32 RR007073; United States / NCI NIH HHS / CA / P01 CA100730-09; United States / NCI NIH HHS / CA / F32 CA130458-01; United States / NCI NIH HHS / CA / F32 CA130458; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] SY7Q814VUP / Calcium
  • [Other-IDs] NLM/ NIHMS270807; NLM/ PMC3057200
  •  go-up   go-down


67. Takasaki Y, Iwanaga M, Imaizumi Y, Tawara M, Joh T, Kohno T, Yamada Y, Kamihira S, Ikeda S, Miyazaki Y, Tomonaga M, Tsukasaki K: Long-term study of indolent adult T-cell leukemia-lymphoma. Blood; 2010 Jun 3;115(22):4337-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term study of indolent adult T-cell leukemia-lymphoma.
  • The long-term prognosis of indolent adult T-cell leukemia-lymphoma (ATL) is not clearly elucidated.
  • From 1974 to 2003, newly diagnosed indolent ATL in 90 patients (65 chronic type and 25 smoldering type) was analyzed.
  • The median survival time was 4.1 years; 12 patients remained alive for more than 10 years, 44 progressed to acute ATL, and 63 patients died.
  • The prognosis of indolent ATL in this study was poorer than expected.
  • These findings suggest that even patients with indolent ATL should be carefully observed in clinical practice.
  • Further studies are required to develop treatments for indolent ATL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348391.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Wada T, Yoshinaga E, Oiso N, Kawara S, Kawada A, Kozuka T: Adult T-cell leukemia-lymphoma associated with follicular mucinosis. J Dermatol; 2009 Dec;36(12):638-42
Genetic Alliance. consumer health - Follicular Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia-lymphoma associated with follicular mucinosis.
  • Follicular mucinosis (alopecia mucinosa) is often associated with malignancies including mycosis fungoides and Sézary syndrome, but not adult T-cell leukemia-lymphoma (ATLL).
  • The patient showed 11% of flower-shaped atypical lymphocytes in blood examination and positive human T-cell leukemia virus type 1 antibody in serology, consistent with the chronic type of ATLL.
  • This case seems to be a very rare association of follicular mucinosis and chronic ATLL, suggesting that malignant T cells may have a feature of folliculotropism as well as epidermotropism.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / complications. Mucinosis, Follicular / complications
  • [MeSH-minor] DNA, Viral / genetics. DNA, Viral / isolation & purification. Human T-lymphotropic virus 1 / genetics. Human T-lymphotropic virus 1 / isolation & purification. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958447.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


69. Mahieux R, Gessain A: Adult T-cell leukemia/lymphoma and HTLV-1. Curr Hematol Malig Rep; 2007 Oct;2(4):257-64
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma and HTLV-1.
  • Human T-cell leukemia/lymphoma virus type 1 (HTLV-1) was the first oncogenic human retrovirus to be discovered, more than 25 years ago.
  • HTLV-1 infects 15 to 20 million individuals worldwide.
  • HTLV-1 causes two major diseases: adult T-cell leukemia/lymphoma (ATLL) and tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM).
  • ATLL can be classified into four major subtypes: a smoldering type, a chronic type, a lymphoma type, and a leukemic type.
  • Because of intrinsic chemoresistance and severe immunosuppression, the survival rate of ATLL patients, especially those who develop the acute leukemic or lymphoma forms, is very poor, and such clonal malignant CD4 expansion remains one of the most severe lymphoproliferations.
  • [MeSH-major] Human T-lymphotropic virus 1 / pathogenicity. Leukemia-Lymphoma, Adult T-Cell / virology
  • [MeSH-minor] Adult. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Humanized. Antibodies, Neoplasm / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. CD4-Positive T-Lymphocytes / virology. Clinical Trials as Topic. Drug Resistance, Neoplasm. Endemic Diseases. Female. Gene Products, tax / physiology. Genes, pX. Humans. Immunoglobulin G / therapeutic use. Immunophenotyping. Immunotherapy. Infant, Newborn. Infectious Disease Transmission, Vertical. Interferon-alpha / therapeutic use. Male. Oxides / therapeutic use. Paraparesis, Tropical Spastic / epidemiology. Paraparesis, Tropical Spastic / virology. Pregnancy. Pregnancy Complications, Infectious. Zidovudine / therapeutic use

  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • Hazardous Substances Data Bank. ZIDOVUDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425378.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Gene Products, tax; 0 / Immunoglobulin G; 0 / Interferon-alpha; 0 / Oxides; 0 / tax protein, Human T-lymphotrophic virus 1; 3A189DH42V / alemtuzumab; 4B9XT59T7S / Zidovudine; CUJ2MVI71Y / daclizumab; S7V92P67HO / arsenic trioxide
  • [Number-of-references] 63
  •  go-up   go-down


70. Shimizu D, Taki T, Utsunomiya A, Nakagawa H, Nomura K, Matsumoto Y, Nishida K, Horiike S, Taniwaki M: Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma. Int J Hematol; 2007 Apr;85(3):212-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of NOTCH1 mutations in adult T-cell leukemia/lymphoma and peripheral T-cell lymphoma.
  • We analyzed NOTCH1 gene mutation in 53 adults with mature T-cell leukemia/lymphoma: 21 patients with adult T-cell leukemia (ATL), 25 with T-cell non-Hodgkin's lymphoma (T-NHL), and 7 with T-cell prolymphocytic leukemia.
  • We detected a nonsense mutation, C7249T (resulting in Q2417X, where X is a termination codon) in the PEST domain of NOTCH1 in an ATL patient and detected a 3-bp deletion (positions 7234-7236) that resulted in deletion of a proline codon at codon 2412 in the PEST domain of NOTCH1 in a patient with a T-NHL, peripheral T-cell lymphoma-unspecified (PTCL-u).
  • We also analyzed the expression of NOTCH1 target genes (HES1, CCND1, and MYC), all of which were expressed in the sample of the PTCL-u patient with the NOTCH1 mutation, but found only MYC to be expressed in the sample from the ATL patient.
  • These findings suggest that nonsense mutation in the PEST domain in the ATL case was associated with NOTCH1 signaling through a pathway different from that for T-cell acute lymphoblastic leukemia (T-ALL).
  • Although NOTCH1 mutation occurs infrequently in mature T-cell leukemia/lymphoma, NOTCH1 may be involved in leukemogenesis associated with various forms of T-cell leukemia/lymphoma rather than only with T-ALL.
  • [MeSH-major] Codon, Nonsense. Leukemia-Lymphoma, Adult T-Cell / genetics. Lymphoma, T-Cell, Peripheral / genetics. Receptor, Notch1 / genetics
  • [MeSH-minor] Adult. DNA Mutational Analysis. Humans

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483057.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon, Nonsense; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


71. Merle H, Donnio A, Gonin C, Jean-Charles A, Panelatti G, Plumelle Y: Retinal vasculitis caused by adult T-cell leukemia/lymphoma. Jpn J Ophthalmol; 2005 Jan-Feb;49(1):41-5
Genetic Alliance. consumer health - Vasculitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retinal vasculitis caused by adult T-cell leukemia/lymphoma.
  • BACKGROUND: To report a case of lymphomatous infiltration and bilateral retinal vasculitis observed among 83 cases of adult T-cell leukemia (ATL) treated in the University Hospital Center in Fort-de-France (Martinique, French West Indies) between 1984 and 2003.
  • CASE: A complete clinical ophthalmologic examination was performed in this patient along with fluorescein angiography.
  • OBSERVATIONS: After being checked for diffuse adenopathies, myodesopsias, and phosphenes, the 35-year-old patient was diagnosed with ATL.
  • The ocular impairment, present since the onset of ATL as peripheral subretinal infiltrates, spread progressively and afferently to the rest of the retina in the form of an essentially venous vasculitis.
  • Impairment of the vitreous was noted only in the end stages of disease progression.
  • CONCLUSION: Among the more than 300 seropositive for human T-cell lymphotropic virus type 1 (HTLV-1) or patients with HTLV-1-associated myelopathy/tropical spastic paraparesis treated at our hospital in the last 20 years, and among the 83 cases of ATL, only this single case of retinal vasculitis associated with HTLV-1 was observed (1/83, 1.2%) in Martinique, confirming the geographic variability of the clinical phenotype of HTLV-1 infection.
  • The incidence of retinal vasculitis in ATL patients may signify an even worse prognosis than initially indicated.
  • [MeSH-major] Human T-lymphotropic virus 1 / isolation & purification. Leukemia-Lymphoma, Adult T-Cell / complications. Retinal Vasculitis / etiology
  • [MeSH-minor] Adult. Antiviral Agents / therapeutic use. Blotting, Western. Drug Therapy, Combination. Enzyme-Linked Immunosorbent Assay. Fatal Outcome. Female. Fluorescein Angiography. HTLV-I Antibodies / blood. Humans. Leukemic Infiltration. Retina / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692773.001).
  • [ISSN] 0021-5155
  • [Journal-full-title] Japanese journal of ophthalmology
  • [ISO-abbreviation] Jpn. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / HTLV-I Antibodies
  •  go-up   go-down


72. Lucas CT, Gillis KJ, Ness JM, Hammers YA, Crawford DF, Kelly DR, Theos A: Adult T-cell leukemia/lymphoma in an adolescent presenting with skin lesions. Pediatr Dermatol; 2008 May-Jun;25(3):373-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma in an adolescent presenting with skin lesions.
  • Adult T-cell leukemia/lymphoma is a T-cell malignancy caused by the human T-cell lymphotropic virus-I.
  • Adult T-cell leukemia/lymphoma is primarily a disease of adults due to the long latency period between initial infection and development of leukemia.
  • We present a case of acute adult T-cell leukemia/lymphoma in an adolescent.
  • Skin lesions had appeared 3 years earlier and were the initial sign of human T-cell lymphotropic virus-I infection and T-cell malignancy.
  • Her disease failed to respond to both intensive chemotherapy and antiviral therapy.
  • Cutaneous lesions are sometimes the initial sign of adult T-cell leukemia/lymphoma and early recognition is imperative.
  • [MeSH-major] HTLV-I Infections / transmission. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Antigens, CD / analysis. Blood Transfusion / adverse effects. Deltaretrovirus Antibodies / analysis. Disease Transmission, Infectious. Fatal Outcome. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Immunophenotyping. Skin / pathology. Skin / virology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18577047.001).
  • [ISSN] 1525-1470
  • [Journal-full-title] Pediatric dermatology
  • [ISO-abbreviation] Pediatr Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Deltaretrovirus Antibodies
  •  go-up   go-down


73. Pezeshkpoor F, Yazdanpanah MJ, Shirdel A: Specific cutaneous manifestations in adult T-cell leukemia/lymphoma. Int J Dermatol; 2008 Apr;47(4):359-62
Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Specific cutaneous manifestations in adult T-cell leukemia/lymphoma.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is an aggressive malignancy which may occur in individuals infected with human T-cell lymphotropic virus type-I (HTLV-I).
  • HTLV-I is endemic in Khorasan, with a frequency of 2.3% in the general population.
  • As specific cutaneous manifestations of lymphoma may occur in a significant number of patients, we studied these manifestations in ATLL patients admitted to the Hematology and Dermatology Departments of Ghaem Hospital, Mashhad, Iran, during 1995-2004.
  • METHODS: In this descriptive study, demographic and clinical information was obtained from 23 patients suffering from ATLL with specific cutaneous lesions (atypical lymphocytes on histopathology of cutaneous lesions), and was analyzed statistically.
  • CONCLUSION: The most common type of specific skin lesion in ATLL was maculopapular eruption, especially with a generalized distribution.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemic Infiltration. Skin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Human T-lymphotropic virus 1 / isolation & purification. Humans. Iran. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377598.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Tanaka Y, Nakasone H, Yamazaki R, Sato K, Sato M, Terasako K, Kimura S, Okuda S, Kako S, Oshima K, Tanihara A, Nishida J, Yoshikawa T, Nakatsura T, Sugiyama H, Kanda Y: Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma. Cancer Res; 2010 Aug 1;70(15):6181-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Single-cell analysis of T-cell receptor repertoire of HTLV-1 Tax-specific cytotoxic T cells in allogeneic transplant recipients with adult T-cell leukemia/lymphoma.
  • Adult T-cell leukemia (ATL) is a lymphoproliferative malignancy associated with human T-cell lymphotropic virus type 1 (HTLV-1) infection.
  • Recently, it has been shown that allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective treatment for ATL, and that HTLV-1 Tax-specific CD8(+) cytotoxic T cells (CTL) contribute to the graft-versus-ATL effect.
  • In the present study, we, for the first time, analyzed the T-cell receptor (TCR) repertoire of isolated Tax(301-309) (SFHSLHLLF)-specific CTLs in HLA-A*2402(+) ATL patients before and after allo-HSCT by single-cell reverse transcription-PCR.
  • In addition, a unique conserved amino acid motif of "P-D/P-R" in TCR-beta complementarity-determining region 3 in either BV7- or BV18-expressing CTLs was observed not only in all of the samples from ATL patients, but also in samples from the same patient before and after HSCT.
  • Furthermore, the P-D/P-R motif-bearing CTL clones established from peripheral blood samples after HSCT exhibited strong killing activity against the HTLV-1-infected T cells of the patient.
  • Hence, Tax(301-309)-specific CTLs in ATL patients might have a preference for TCR construction and induce strong immune responses against the HTLV-1-infected T cells of patients, which contribute to the graft-versus-ATL effects after allo-HSCT.
  • [MeSH-major] Gene Products, tax / immunology. Hematopoietic Stem Cell Transplantation. Human T-lymphotropic virus 1 / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes, Cytotoxic / immunology
  • [MeSH-minor] Amino Acid Motifs. HLA-A Antigens / immunology. HLA-A24 Antigen. Humans. Peptide Fragments / immunology. Receptors, Antigen, T-Cell / immunology. Receptors, Antigen, T-Cell, alpha-beta / immunology

  • Immune Epitope Database and Analysis Resource. gene/protein/disease-specific - Related Immune Epitope Information .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647322.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gene Products, tax; 0 / HLA-A Antigens; 0 / HLA-A*24:02 antigen; 0 / HLA-A24 Antigen; 0 / Peptide Fragments; 0 / Receptors, Antigen, T-Cell; 0 / Receptors, Antigen, T-Cell, alpha-beta; 0 / tax protein, Human T-lymphotrophic virus 1
  •  go-up   go-down


75. Tobinai K: Current management of adult T-cell leukemia/lymphoma. Oncology (Williston Park); 2009 Dec;23(14):1250-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current management of adult T-cell leukemia/lymphoma.
  • When oncologists diagnose patients suspected of lymphoid malignancy, it is important to consider the possibility of adult T-cell leukemia/lymphoma (ATL) with a routine check for serum human T-cell lymphotropic virus type 1 (HTLV-1) antibody.
  • The following points are essential for the diagnosis of ATL:.
  • (1) cytologically or histologically proven peripheral T-cell malignancy, and (2) positivity for anti-HTLV-1 antibody.
  • When a patient is diagnosed with ATL, it is important to make an accurate diagnosis of clinical subtype in order to make appropriate treatment decisions.
  • For patients with smoldering or chronic type ATL, close observation with careful monitoring for opportunistic infections is recommended.
  • For patients with the acute or lymphoma type requiring therapy, enrollment in a clinical trial is recommended.
  • When there is no active trial or the patient is ineligible for a trial, we recommend intensive chemotherapy used for aggressive non-Hodgkin lymphoma such as the LSG15 regimen (VCAP-AMP-VECP) based on a recent phase III study.
  • Because most patients with ATL are not curable with current chemotherapy regimens, it is reasonable to consider the applicability of allogeneic stem cell transplantation inpatients who show responses to chemotherapy.
  • For relapsed or refractory patients, enrollment in a new-agent trial should be considered in addition to stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Deltaretrovirus Antibodies / blood. Female. Hematopoietic Stem Cell Transplantation. Humans. Kaplan-Meier Estimate. Male. Transplantation, Homologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2009 Dec;23(14):1267, 1270 [20120839.001]
  • [CommentIn] Oncology (Williston Park). 2009 Dec;23(14):1256, 1261, 1266 [20120838.001]
  • (PMID = 20120837.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Deltaretrovirus Antibodies
  •  go-up   go-down


76. Kohno T, Yamada Y, Tawara M, Takasaki Y, Kamihira S, Tomonaga M, Matsuyama T: Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma. Leuk Res; 2007 Dec;31(12):1625-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of p14ARF as a key event for the progression of adult T cell leukemia/lymphoma.
  • These results indicate that the inactivation of p14ARF plays a key role in the progression of ATLL.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Leukemia-Lymphoma, Adult T-Cell / etiology. Tumor Suppressor Protein p14ARF / metabolism
  • [MeSH-minor] Acute Disease. Adult. Chronic Disease. Disease Progression. Genes, p53 / genetics. Humans. Mutation. Polymerase Chain Reaction. Prognosis. RNA, Messenger / analysis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246599.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p14ARF
  •  go-up   go-down


77. Fujiwara H, Nakamura D, Kukita T, Hamada H, Ozaki A, Matsushita K, Matsumoto T, Tei C: Immunosuppressive treatment for mixed connective tissue disease may facilitate the development of adult T cell leukemia/lymphoma in a HTLVI carrier. Intern Med; 2006;45(5):297-301
Hazardous Substances Data Bank. METHYLPREDNISOLONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunosuppressive treatment for mixed connective tissue disease may facilitate the development of adult T cell leukemia/lymphoma in a HTLVI carrier.
  • A 66-year-old woman who was positive for human T-lymphotropic virus type I (HTLV-I) antibody developed mixed connective tissue disease (MCTD) with interstitial pneumonia, and was successfully treated with corticosteroid.
  • One year later, under maintenance treatment of prednisolone (PSL), she contracted acute type adult Tcell leukemia/lymphoma (ATLL) without flaring of MCTD.
  • MCTD is considered to be as one of the HTL-V-I-related inflammatory diseases, however the development of ATLL during the treatment of HTL-V-I-related MCTD has not been well studied.
  • Here, we review the literature and raise the issue of the mutual interactions between MCTD-causative anti-HTLV-I immune response and anti-ATLL immune response.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / immunology. Mixed Connective Tissue Disease / drug therapy

  • Genetic Alliance. consumer health - Mixed connective tissue disease.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16595998.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 0 / Receptors, Interleukin-2; 9PHQ9Y1OLM / Prednisolone; EC 2.7.1.21 / Thymidine Kinase; X4W7ZR7023 / Methylprednisolone
  • [Number-of-references] 21
  •  go-up   go-down


78. Salcedo-Cifuentes M, Cabrera J, Cuesta-Astroz Y, Carrasca E, Eizuru Y, Domínguez MC, Sánchez A, García-Vallejo F: [Clonal expansion and genomic characterization of the human T-cell lymphotropic virus type I during the integration process in adult T-cell leukemia/lymphoma]. Biomedica; 2009 Jun;29(2):218-31

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clonal expansion and genomic characterization of the human T-cell lymphotropic virus type I during the integration process in adult T-cell leukemia/lymphoma].
  • [Transliterated title] Expansión clónica y caracterización genómica del proceso de integración del virus linfotrópico humano tipo I en la leucemia/linfoma de células T en adultos.
  • INTRODUCTION: Although the integration of human T-cell lymphotropic virus type I into the T-cells is not a random process, the mechanistic details are not understood.
  • OBJECTIVES: The characteristics of the flanking host chromatin were evaluated at the integration sites in adult T-cell leukaemia/lymphoma (ATLL) patients infected with the virus.
  • MATERIALS AND METHODS: From seven leukemic Colombian patients positive for the human T-cell lymphotropic virus type I (HTLV-I), lymphocyte DNA samples were extracted and amplified by inverse polymerase chain reaction (IPCR).
  • Clonal expansion and human genome nucleotide composition in an extension of 50 bp was determined.
  • To establish the characteristics of the human genome flanking provirus, 61 IPCR sequences from Colombian and Japanese ATLL patients, were analyzed in silico to obtain insights about the genomic structure, functions and nature of associated chromatin.
  • RESULTS: The clonal expansion of cell clones was predominantly oligoclonal.
  • Fifty percent of the proviral integrations were associated with chromosomes of A and B groups.
  • Viral DNA integration tended to favor exons of genes that replicated early, controlled the cell cycle, or were involved in signal transduction.
  • CONCLUSIONS: The results indicated that HTLV-I integration was preferentially directed towards genomic environments with high C:G content, and toward genes that replicate early, regulate cell cycle or involved with signal transduction.
  • [MeSH-major] Genome, Viral. Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / virology. Proviruses / genetics. T-Lymphocytes / virology. Virus Integration / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Base Composition. Cell Transformation, Viral / genetics. Child. Child, Preschool. Clone Cells / virology. DNA Replication / genetics. DNA, Neoplasm / genetics. DNA, Viral / genetics. Female. Genes, cdc. Genes, pX. Humans. Male. Middle Aged. Sequence Alignment. Sequence Analysis, DNA. Sequence Homology, Nucleic Acid. Signal Transduction / genetics. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20128347.001).
  • [ISSN] 0120-4157
  • [Journal-full-title] Biomédica : revista del Instituto Nacional de Salud
  • [ISO-abbreviation] Biomedica
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Colombia
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA, Viral
  •  go-up   go-down


79. Alduaij A, Butera JN, Treaba D, Castillo J: Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature. Clin Lymphoma Myeloma Leuk; 2010 Dec;10(6):480-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission in two cases of adult T-cell leukemia/lymphoma treated with hyper-CVAD: a case report and review of the literature.
  • BACKGROUND: Acute T-cell leukemia/lymphoma (ATLL) is a post thymic (peripheral) T-cell neoplasm caused by human T-cell lymphotropic virus type 1 (HTLV-1).
  • However, its prognosis is poor and median survival in the aggressive variants of ATLL is only 6-10 months.
  • Yet, there is little reported experience with hyper-CVAD regimen in ATLL.
  • CASE REPORTS: We present 2 patients diagnosed with ATLL who were treated with hyper-CVAD chemotherapy and have achieved a durable complete remission.
  • We also review the past published experience with the hyper-CVAD regimen in patients with ATLL.
  • CONCLUSION: A commonly used chemotherapy regimen for aggressive hematologic malignancies, hyper-CVAD, can induce durable remissions in patients with ATLL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Female. Hematopoietic Stem Cell Transplantation / methods. Humans. Male. Middle Aged. Remission Induction. Transplantation, Homologous. Treatment Outcome. Vincristine / administration & dosage

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21156467.001).
  • [ISSN] 2152-2669
  • [Journal-full-title] Clinical lymphoma, myeloma & leukemia
  • [ISO-abbreviation] Clin Lymphoma Myeloma Leuk
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


80. Machijima Y, Ishikawa C, Sawada S, Okudaira T, Uchihara JN, Tanaka Y, Taira N, Mori N: Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol. Retrovirology; 2009;6:7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-adult T-cell leukemia/lymphoma effects of indole-3-carbinol.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is a malignancy derived from T cells infected with human T-cell leukemia virus type 1 (HTLV-1), and it is known to be resistant to standard anticancer therapies.
  • The aim of this study was to determine the potential anti-ATLL effects of I3C both in vitro and in vivo.
  • RESULTS: In the in vitro study, I3C inhibited cell viability of HTLV-1-infected T-cell lines and ATLL cells in a dose-dependent manner.
  • Importantly, I3C did not exert any inhibitory effect on uninfected T-cell lines and normal peripheral blood mononuclear cells.
  • The induced apoptosis was associated with activation of caspase-3, -8 and -9, and poly(ADP-ribose) polymerase cleavage.
  • Inoculation of HTLV-1-infected T cells in mice with severe combined immunodeficiency resulted in tumor growth.
  • CONCLUSION: Our preclinical data suggest that I3C could be potentially a useful chemotherapeutic agent for patients with ATLL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cell Survival / drug effects. Human T-lymphotropic virus 1 / drug effects. Indoles / pharmacology. Indoles / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. T-Lymphocytes
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Cycle Proteins / drug effects. Cell Line, Transformed. Cell Line, Tumor. G1 Phase / drug effects. Humans. Mice. Mice, SCID. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):123-9 [10926790.001]
  • [Cites] EMBO J. 2000 Dec 1;19(23):6351-60 [11101508.001]
  • [Cites] Virology. 2001 Jan 5;279(1):38-46 [11145887.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1094-102 [11314046.001]
  • [Cites] Histol Histopathol. 2001 Apr;16(2):595-601 [11332715.001]
  • [Cites] Oncogene. 2001 Apr 19;20(17):2055-67 [11360190.001]
  • [Cites] Br J Haematol. 2001 May;113(2):375-82 [11380402.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2390-400 [11402335.001]
  • [Cites] Oncogene. 2001 May 24;20(23):2927-36 [11420705.001]
  • [Cites] FEBS Lett. 2004 Mar 26;562(1-3):165-70 [15044019.001]
  • [Cites] Cancer Sci. 2004 Jul;95(7):596-601 [15245597.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5233-41 [15297427.001]
  • [Cites] J Natl Cancer Inst. 1975 Apr;54(4):985-8 [1127728.001]
  • [Cites] Cancer Res. 1978 May;38(5):1410-3 [416908.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Dec;77(12):7415-9 [6261256.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Science. 1982 Aug 20;217(4561):737-9 [6980467.001]
  • [Cites] Int J Cancer. 1984 Aug 15;34(2):221-8 [6088403.001]
  • [Cites] Jpn J Cancer Res. 1990 Mar;81(3):225-31 [2161813.001]
  • [Cites] Cell. 1996 Mar 22;84(6):853-62 [8601309.001]
  • [Cites] J Biol Chem. 1996 Apr 12;271(15):9090-9 [8621559.001]
  • [Cites] J Immunol. 1996 Nov 1;157(9):3980-7 [8892631.001]
  • [Cites] Cancer Lett. 1997 Sep 16;118(1):87-94 [9310264.001]
  • [Cites] J Exp Med. 1998 Jul 6;188(1):211-6 [9653098.001]
  • [Cites] Mol Cell Biol. 1999 Apr;19(4):2690-8 [10082535.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2360-8 [10090947.001]
  • [Cites] Cancer Res. 1999 Aug 15;59(16):3991-7 [10463597.001]
  • [Cites] J Nutr. 2004 Dec;134(12 Suppl):3493S-3498S [15570059.001]
  • [Cites] J Nutr Biochem. 2005 Feb;16(2):65-73 [15681163.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):967-74 [15729715.001]
  • [Cites] Blood. 2005 Jul 15;106(2):641-9 [15811958.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1953-60 [16103443.001]
  • [Cites] Eur J Cancer. 2005 Sep;41(13):1842-53 [16087329.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5952-64 [16155602.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5965-75 [16155603.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):5976-85 [16155604.001]
  • [Cites] Cell Cycle. 2005 Sep;4(9):1201-15 [16082211.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8521-7 [16322316.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 17;103(3):720-5 [16407133.001]
  • [Cites] Int J Gynecol Cancer. 2006 Mar-Apr;16(2):786-90 [16681761.001]
  • [Cites] Mol Cancer Ther. 2006 Nov;5(11):2747-56 [17121921.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2477-81 [17164373.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Retrovirology. 2007;4:92 [18078517.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):19-26 [18440219.001]
  • [Cites] Retrovirology. 2008;5:76 [18702816.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2286-94 [18771528.001]
  • [Cites] Jpn J Cancer Res. 2000 Jan;91(1):34-40 [10744042.001]
  • [Cites] Blood. 2000 Jun 15;95(12):3915-21 [10845928.001]
  • [Cites] Food Chem Toxicol. 2000 Jan;38(1):15-23 [10685010.001]
  • (PMID = 19146708.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cell Cycle Proteins; 0 / Indoles; C11E72455F / indole-3-carbinol
  • [Other-IDs] NLM/ PMC2635345
  •  go-up   go-down


81. Townsend AR, Millward M, Price T, Mainwaring P, Spencer A, Longenecker A, Palladino MA, Lloyd GK, Spear MA, Padrik P: Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). J Clin Oncol; 2009 May 20;27(15_suppl):3582

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm).
  • Preclinical research suggests improvements in therapeutic ratio and activity in hematologic and solid tumor models, leading to clinical trials in patients with myeloma, lymphomas, leukemias, and solid tumors.
  • METHODS: Patients with solid tumor, lymphoma or leukemia diagnoses without standard treatment options were treated with IV NPI on Days 1, 8 and 15 of 28-day cycles in a 3+3 design dose escalation to a Recommended Phase 2 Dose (RP2D).
  • Enrollment then began in 10 patient lymphoma and CLL RP2D cohorts.
  • Stable disease was induced in 31% of patients, including one each with mantle cell, Hodgkin's lymphoma, follicular lymphoma, sarcoma, prostate carcinoma, and two with melanoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961753.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Utsunomiya A, Ishida T, Inagaki A, Ishii T, Yano H, Komatsu H, Iida S, Yonekura K, Takeuchi S, Takatsuka Y, Ueda R: Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res; 2007 Jul;31(7):915-20
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor.
  • We investigated the clinical significance of a blood eosinophilia in a cohort of 158 consecutive patients with adult T-cell leukemia/lymphoma (ATLL), and multivariate analysis revealed that a blood eosinophilia was an independent and a significant unfavorable prognostic factor.
  • The present study shows that measurement of the blood eosinophil count is useful for predicting the prognosis and for determining a suitable treatment strategy for ATLL patients.
  • [MeSH-major] Eosinophilia / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cohort Studies. Eosinophils / pathology. Female. Humans. L-Lactate Dehydrogenase / blood. Leukocyte Count. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123603.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


83. Ishitsuka K, Fukushima T, Tsukasaki K, Tobinai K: Is zidovudine and interferon-alfa the gold standard for adult T-cell leukemia-lymphoma? J Clin Oncol; 2010 Dec 20;28(36):e765; author reply e766
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is zidovudine and interferon-alfa the gold standard for adult T-cell leukemia-lymphoma?
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Interferon-alpha / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Zidovudine / therapeutic use
  • [MeSH-minor] Adult. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2010 Sep 20;28(27):4177-83 [20585095.001]
  • (PMID = 20921454.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 4B9XT59T7S / Zidovudine
  •  go-up   go-down


84. Keramati MR, Sadeghian MH, Ayatollahi H: Clinical and laboratory features in adult T-cell leukemia/lymphoma in Khorasan, Iran. Leuk Lymphoma; 2010 Apr;51(4):727-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical and laboratory features in adult T-cell leukemia/lymphoma in Khorasan, Iran.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. HTLV-I Infections / blood. HTLV-I Infections / complications. HTLV-I Infections / pathology. Humans. Iran. Male. Middle Aged. Neoplasm Staging. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20178409.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


85. Barnes JA, Abramson JS: Adult T-cell leukemia/lymphoma: complexities in diagnosis and novel treatment strategies. Oncology (Williston Park); 2009 Dec;23(14):1267, 1270
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma: complexities in diagnosis and novel treatment strategies.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Adult. Deltaretrovirus Antibodies / blood. Diagnosis, Differential. Emigrants and Immigrants. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Transplantation, Homologous. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Oncology (Williston Park). 2009 Dec;23(14):1250-6 [20120837.001]
  • (PMID = 20120839.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Deltaretrovirus Antibodies
  •  go-up   go-down


86. Kawai K, Uchida Y, Yonekura K, Virtanen S, Tähtinen M, Krohn K, Ranki A, Kanekura T: Cutaneous-type adult T-cell leukemia/lymphoma does not primarily show deletion of NAV3 gene. J Invest Dermatol; 2010 Jan;130(1):316-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous-type adult T-cell leukemia/lymphoma does not primarily show deletion of NAV3 gene.
  • [MeSH-major] Gene Deletion. Leukemia-Lymphoma, Adult T-Cell / genetics. Membrane Proteins / genetics. Nerve Tissue Proteins / genetics. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19626031.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / NAV3 protein, human; 0 / Nerve Tissue Proteins
  •  go-up   go-down


87. Tarhini M, Kooshyar MM, Farzadnia M, Maleki M, Kchour G, Tabatabaee A, Otrock ZK, Bazarbachi A: Adult T cell leukemia-lymphoma with testicular involvement. Ann Hematol; 2009 Jun;88(6):591-2
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T cell leukemia-lymphoma with testicular involvement.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Testicular Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941745.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  •  go-up   go-down


88. Kim YJ, Hwang ES, Kim IH, Yu DS: CD4/CD8 double-positive, acute type of adult T-cell leukemia/lymphoma with extensive cutaneous involvement. Int J Dermatol; 2006 Oct;45(10):1193-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD4/CD8 double-positive, acute type of adult T-cell leukemia/lymphoma with extensive cutaneous involvement.
  • [MeSH-major] Antigens, CD4 / immunology. Antigens, CD8 / immunology. Leukemia-Lymphoma, Adult T-Cell / immunology. Lymphoma, T-Cell, Cutaneous / immunology. Skin Neoplasms / immunology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17040438.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Antigens, CD8
  •  go-up   go-down


89. Khattab TM, Jastaniah WA, Felimban SK, Elemam N, Abdullah K, Ahmed B: How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia. J Clin Oncol; 2009 May 20;27(15_suppl):10048

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How could improvement in the management of T-cell acute lymphoblastic leukemia be achieved? Experience of Princess Nourah Oncology Center, National Guard Hospital, Jeddah, Saudi Arabia.
  • : 10048 Background: T-cell acute lymphoblastic leukemia (T-ALL) is representing 10-15% of pediatric ALL.
  • METHODS: Retrospective review of all patients files diagnosed with T-ALL from 1989 until now with data collection including; sex, age, white cell count (WBCs), CNS disease, type of protocol used, length of survival, overall survival, cause of death (toxic, disease).
  • Median WBCs 50,000/Cmm (range: 1.500-619,000/Cmm) and positive CNS at diagnosis 10/52 (20%).
  • Overall survival 27/52 (52%) and 25 pts. died (48%); 15 secondary to disease recurrence (9 on UKALL, 4 BFM, 2 CCG 1961); 4 during induction, 1 fulminant hepatic failure, 1 tumor lysis syndrome, and 4 due to toxicities (mucormycosis, staphylococcal toxic shock syndrome, CMV pneumonia, pseudomonas sepsis).
  • Using augmented therapy based on CCG1961 was associated with better outcome.
  • Further risk and response stratification in addition to intensification of therapy for T-cell ALL in our center may prove to be beneficial.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962474.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Ishitsuka K, Suzumiya J, Aoki M, Ogata K, Hara S, Tamura K: Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica; 2007 May;92(5):719-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic potential of arsenic trioxide with or without interferon-alpha for relapsed/refractory adult T-cell leukemia/lymphoma.
  • Arsenic trioxide (As2O3) with or without interferon-a (IFN) was given to 4 patients with relapsed/refractory adult T-cell leukemia/lymphoma (ATLL).
  • Treatment with As2O3 and IFN showed an encouraging response in two moderately-aggressive ATLL patients, while As2O3 alone was ineffective in two patients with very aggressive and rapidly progressing ATLL.
  • Further studies are needed to clarify the role of As2O3 and its usefulness when combined with IFN for the treatment of ATLL.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Arsenicals / therapeutic use. Interferon-alpha / administration & dosage. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Oxides / therapeutic use. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor / drug effects. Disease Progression. Female. Humans. Male. Recurrence. Thrombocytopenia / drug therapy. Thrombocytopenia / etiology

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ARSENIC TRIOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17488707.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Letter
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arsenicals; 0 / Interferon-alpha; 0 / Oxides; S7V92P67HO / arsenic trioxide
  •  go-up   go-down


91. Fett NM, Siddiqui J, Creswell CH, Zhang D, Lloyd R, Wood GS: Adult T-cell leukemia/lymphoma in a patient from Romania: a case report and review of the literature. J Cutan Pathol; 2008 Oct;35 Suppl 1:32-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma in a patient from Romania: a case report and review of the literature.
  • Adult T-cell leukemia/lymphoma (ATLL) is a rare malignancy caused by human T-cell leukemia virus-1.
  • ATLL is endemic to Japan, and to date, there are only four case reports of patients from Romania who have developed ATLL.
  • Here, we describe a woman living in Madison, Wisconsin, originally from Romania, who presented with an atypical papulosquamous eruption and was ultimately diagnosed with smoldering ATLL.
  • Narrow-band ultraviolet-B (UV-B) therapy and mid-potency topical steroids resulted in skin clearing for approximately 5 months after diagnosis; however, she subsequently relapsed with disease refractory to both narrow band UV-B and psoralen plus ultraviolet A (PUV-A), progressed to acute ATLL and expired secondary to complications.
  • [MeSH-major] HTLV-I Infections / complications. Leukemia-Lymphoma, Adult T-Cell / pathology. Leukemia-Lymphoma, Adult T-Cell / physiopathology. Ultraviolet Therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Adult. Female. Flow Cytometry. Humans. Immunohistochemistry. Polymerase Chain Reaction. Respiratory Tract Infections / pathology. Romania. Vitiligo / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544058.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones
  •  go-up   go-down


92. Shimizu S, Yasui C, Koizumi K, Ikeda H, Tsuchiya K: Cutaneous-type adult T-cell leukemia/lymphoma presenting as a solitary large skin nodule: a review of the literature. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S115-7
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous-type adult T-cell leukemia/lymphoma presenting as a solitary large skin nodule: a review of the literature.
  • Adult T-cell leukemia/lymphoma (ATLL) often involves the skin.
  • While the clinical manifestations of the cutaneous-type ATLL are variable, including multiple papules, nodules, plaques, or erythroderma, a solitary skin nodule alone is rare, and only 2 cases have been reported in the literature.
  • We present a 58-year-old Japanese patient with cutaneous-type ATLL that presented as a large, solitary skin nodule as the sole clinical feature.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938020.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


93. Idutsu K, Abe Y, Otonari J, Tachikawa Y, Ohtsuka R, Choi I, Muta K, Takayanagi R: [Human herpesvirus 6 encephalitis in a patient with adult T-cell leukemia/lymphoma]. Rinsho Ketsueki; 2007 Aug;48(8):664-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Human herpesvirus 6 encephalitis in a patient with adult T-cell leukemia/lymphoma].
  • Human herpesvirus 6 (HHV-6) reactivates in immunocompromised patients, and HHV-6 encephalitis has often been reported as a complication of transplantation.
  • We describe a 37-year-old woman with the acute type of adult T-cell leukemia/lymphoma who developed HHV-6 encephalitis before chemotherapy.
  • HHV-6 encephalitis should be listed as a differential diagnosis of encephalopathy developing in immunocompromised patients.
  • [MeSH-major] Encephalitis, Herpes Simplex / complications. Herpesvirus 6, Human. Leukemia-Lymphoma, Adult T-Cell / complications. Opportunistic Infections / complications. Roseolovirus Infections / complications
  • [MeSH-minor] Adult. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867305.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


94. Kawakami T, Kawanabe T, Soma Y: Granuloma annulare-like skin lesions as an initial manifestation in a Japanese patient with adult T-cell leukemia/lymphoma. J Am Acad Dermatol; 2009 May;60(5):848-52
Genetic Alliance. consumer health - Granuloma Annulare.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granuloma annulare-like skin lesions as an initial manifestation in a Japanese patient with adult T-cell leukemia/lymphoma.
  • Histologic examination revealed epithelioid cell granulomas associated with dense atypical lymphocytes in the dermis.
  • Human T-cell leukemia virus type I proviral DNA was detected in the blood and cerebrospinal fluid by Southern blot analysis and polymerase chain reaction assay.
  • The patient was given the diagnosis of adult T-cell leukemia/lymphoma based on the initial cutaneous manifestations.
  • The granuloma annulare-like skin lesions in our patient could be considered as a peculiar immunologic hypersensitivity reaction of the host against the tumor cells or persistent human T-cell leukemia virus type I viral antigens.
  • Dermatologists should be aware that this skin condition may be an initial manifestation of adult T-cell leukemia/lymphoma.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / pathology. Skin / pathology
  • [MeSH-minor] Aged. Antigens, CD3 / analysis. Antigens, CD4 / analysis. Antigens, CD5 / analysis. Blotting, Southern. DNA, Viral / analysis. Human T-lymphotropic virus 1 / genetics. Humans. Immunohistochemistry. Interleukin-2 Receptor alpha Subunit / analysis. Male. Polymerase Chain Reaction. Proviruses / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19389526.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD5; 0 / DNA, Viral; 0 / Interleukin-2 Receptor alpha Subunit
  •  go-up   go-down


95. Shahnaz S, Reich D, Arévalo-Valencia D, Kucinska S, Tulczynska J, Fleischman J: HTLV-1-associated adult T cell leukemia lymphoma presenting as granulomatous pneumocystis jiroveci pneumonia (PJP) and hypercalcemia. J Gen Intern Med; 2007 Mar;22(3):420-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HTLV-1-associated adult T cell leukemia lymphoma presenting as granulomatous pneumocystis jiroveci pneumonia (PJP) and hypercalcemia.
  • BACKGROUND: Since the initial description of human T cell lymphotropic virus (HTLV-1), clusters of this infection have been detected globally.
  • Unlike HIV infection, most patients infected with HTLV-1 remain asymptomatic throughout their lifetime.
  • CASE REPORT: We report the case of a 39-year-old Afro-Caribbean man with HTLV-1 infection presenting as hypercalcemia and granulomatous pneumocystis jiroveci pneumonia.
  • HTLV-1-associated adult T cell leukemia lymphoma (ATLL) was diagnosed in this patient by bone marrow and lymph node biopsy.
  • This is believed to be the first description of this type of reaction to pneumocystis jiroveci in a HTLV-1-infected ATLL patient.
  • [MeSH-major] HTLV-I Infections / diagnosis. Hypercalcemia / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Pneumocystis jirovecii. Pneumonia, Pneumocystis / diagnosis
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1994 Aug;14(5-6):395-400 [7812198.001]
  • [Cites] Leuk Lymphoma. 1994 Feb;12(5-6):471-6 [8180610.001]
  • [Cites] Clin Infect Dis. 1996 Jun;22(6):1111-2 [8783726.001]
  • [Cites] J Clin Invest. 1996 Oct 1;98(7):1544-9 [8833902.001]
  • [Cites] Leukemia. 1997 Mar;11(3):453-4 [9067590.001]
  • [Cites] Int J Hematol. 1997 Oct;66(3):257-78 [9401272.001]
  • [Cites] Aust N Z J Med. 1999 Feb;29(1):102-3 [10200829.001]
  • [Cites] Intern Med. 1999 Feb;38(2):83-5 [10225661.001]
  • [Cites] Semin Neurol. 2005 Sep;25(3):315-27 [16170744.001]
  • [Cites] Eur Respir J. 2000 Jan;15(1):213-6 [10678649.001]
  • [Cites] Leuk Lymphoma. 2001 Apr;41(3-4):435-8 [11378559.001]
  • [Cites] Am J Kidney Dis. 2002 Feb;39(2):E8 [11840399.001]
  • [Cites] Thorax. 2002 May;57(5):435-7 [11978921.001]
  • [Cites] J R Soc Med. 2003 Mar;96(3):126-7 [12612113.001]
  • [Cites] Am J Clin Pathol. 1975 Mar;63(3):384-90 [1090147.001]
  • [Cites] J Clin Invest. 1986 Aug;78(2):592-6 [3016032.001]
  • [Cites] Cancer Res. 1989 Jul 15;49(14):3849-52 [2544261.001]
  • [Cites] Semin Diagn Pathol. 1989 Aug;6(3):273-86 [2678337.001]
  • [Cites] Arch Pathol Lab Med. 1989 Nov;113(11):1281-4 [2684091.001]
  • [Cites] J Exp Med. 1990 Sep 1;172(3):759-65 [2388034.001]
  • [Cites] Br J Cancer. 1991 Oct;64(4):745-8 [1911223.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] J La State Med Soc. 1992 Jan;144(1):35-8 [1538186.001]
  • [Cites] J Biol Chem. 1993 Jan 15;268(2):1174-9 [8380405.001]
  • [Cites] Blood. 1993 Feb 15;81(4):1017-24 [8427983.001]
  • [Cites] Endocrinology. 1993 Jun;132(6):2551-6 [8099324.001]
  • [Cites] J Biol Chem. 1993 Aug 5;268(22):16730-6 [8393873.001]
  • [Cites] Clin Infect Dis. 1995 Oct;21(4):1014-6 [8645790.001]
  • (PMID = 17356979.001).
  • [ISSN] 1525-1497
  • [Journal-full-title] Journal of general internal medicine
  • [ISO-abbreviation] J Gen Intern Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1824742
  •  go-up   go-down


96. Zimmerman B, Niewiesk S, Lairmore MD: Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma. Vet Pathol; 2010 Jul;47(4):677-89
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mouse models of human T lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma.
  • Human T-lymphotropic virus type-1 (HTLV-1), the first human retrovirus discovered, is the causative agent of adult T-cell leukemia/lymphoma (ATL) and a number of lymphocyte-mediated inflammatory conditions including HTLV-1-associated myelopathy/tropical spastic paraparesis.
  • Development of animal models to study the pathogenesis of HTLV-1-associated diseases has been problematic.
  • Mechanisms of early infection and cell-to-cell transmission can be studied in rabbits and nonhuman primates, but lesion development and reagents are limited in these species.
  • The mouse provides a cost-effective, highly reproducible model in which to study factors related to lymphoma development and the preclinical efficacy of potential therapies against ATL.
  • Expansion of various strains of immunodeficient mice has accelerated the testing of drugs and targeted therapy against ATL.
  • This review compares various mouse models to illustrate recent advances in the understanding of HTLV-1-associated ATL development and how improvements in these models are critical to the future development of targeted therapies against this aggressive T-cell lymphoma.

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2005 Feb 1;105(3):1231-6 [15383455.001]
  • [Cites] Retrovirology. 2005;2:16 [15743528.001]
  • [Cites] Carcinogenesis. 2005 Aug;26(8):1382-8 [15831528.001]
  • [Cites] Leukemia. 2005 Aug;19(8):1384-90 [15959532.001]
  • [Cites] Immunol Res. 2005;32(1-3):217-23 [16106073.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6005-15 [16155607.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6026-34 [16155609.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6047-57 [16155611.001]
  • [Cites] Blood. 2005 Oct 1;106(7):2462-71 [15956280.001]
  • [Cites] Nutr Cancer. 2005;52(2):189-201 [16201850.001]
  • [Cites] J Biol Chem. 2005 Oct 21;280(42):35713-22 [16105841.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3380-2 [16076875.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4294-302 [16118323.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):765-72 [16106398.001]
  • [Cites] Blood. 2006 Jan 15;107(2):716-24 [16174765.001]
  • [Cites] J Virol. 2006 Apr;80(7):3469-76 [16537614.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):704-12 [16546985.001]
  • [Cites] Nat Med. 2006 Apr;12(4):466-72 [16550188.001]
  • [Cites] J Virol. 2006 Nov;80(21):10683-91 [16943297.001]
  • [Cites] Blood. 2006 Dec 15;108(13):3979-82 [16917009.001]
  • [Cites] Br J Haematol. 2007 Feb;136(3):424-32 [17233845.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):270-80 [17384582.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Feb;87(3):1071-5 [2300570.001]
  • [Cites] Ann Neurol. 1990 Jul;28(1):50-6 [2375633.001]
  • [Cites] Blood. 1990 Oct 15;76(8):1657-61 [1976391.001]
  • [Cites] Blood. 1995 Sep 15;86(6):2350-7 [7662981.001]
  • [Cites] Blood. 1996 Feb 1;87(3):956-67 [8562967.001]
  • [Cites] Intern Med. 1995 Oct;34(10):947-52 [8563094.001]
  • [Cites] Intervirology. 1995;38(3-4):229-37 [8682621.001]
  • [Cites] Jpn J Cancer Res. 1996 Sep;87(9):887-92 [8878449.001]
  • [Cites] J Clin Immunol. 1996 Nov;16(6):305-14 [8946274.001]
  • [Cites] Leukemia. 1996 Dec;10(12):1971-4 [8946939.001]
  • [Cites] Virology. 1996 Dec 15;226(2):167-75 [8955035.001]
  • [Cites] Cancer Res. 2000 Dec 15;60(24):6977-84 [11156399.001]
  • [Cites] Cancer Treat Res. 2001;104:75-88 [11191136.001]
  • [Cites] Leuk Res. 2001 Apr;25(4):323-31 [11248329.001]
  • [Cites] Am J Pathol. 2001 Jun;158(6):2219-28 [11395400.001]
  • [Cites] Blood. 2001 Aug 15;98(4):1200-8 [11493471.001]
  • [Cites] Cancer Res. 2002 Feb 15;62(4):1083-6 [11861386.001]
  • [Cites] Nat Med. 2002 May;8(5):509-13 [11984596.001]
  • [Cites] Leuk Res. 2002 Jun;26(6):561-7 [12007504.001]
  • [Cites] Blood. 2002 Jul 1;100(1):208-16 [12070029.001]
  • [Cites] Microbiol Mol Biol Rev. 2002 Sep;66(3):396-406, table of contents [12208996.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3175-82 [12384415.001]
  • [Cites] J Infect Dis. 2002 Nov 15;186(10):1514-7 [12404172.001]
  • [Cites] Leukemia. 2003 Jan;17(1):26-38 [12529656.001]
  • [Cites] Int J Cancer. 2007 May 15;120(10):2251-61 [17278100.001]
  • [Cites] Cancer Sci. 2007 Jun;98(6):772-8 [17388788.001]
  • [Cites] Rev Med Virol. 2007 Sep-Oct;17(5):301-11 [17621367.001]
  • [Cites] Am J Hematol. 2007 Oct;82(10):929-31 [17617788.001]
  • [Cites] Int J Cancer. 2007 Nov 15;121(10):2205-11 [17657714.001]
  • [Cites] Cancer Lett. 2007 Nov 18;257(2):206-15 [17764832.001]
  • [Cites] Gene Ther. 2007 Dec;14(23):1662-7 [17898798.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11859-66 [18089816.001]
  • [Cites] Eur J Haematol. 2008 Mar;80(3):185-96 [18081707.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2702-12 [18798263.001]
  • [Cites] Blood. 2008 Nov 1;112(9):3788-97 [18689544.001]
  • [Cites] J Virol. 2008 Dec;82(23):11958-63 [18922876.001]
  • [Cites] Cancer Sci. 2008 Nov;99(11):2286-94 [18771528.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1287-93 [18948574.001]
  • [Cites] Blood. 2009 Feb 12;113(7):1493-500 [18971418.001]
  • [Cites] Front Biosci (Landmark Ed). 2009;14:1479-89 [19273141.001]
  • [Cites] Retrovirology. 2009;6:19 [19228429.001]
  • [Cites] Nature. 1990 Nov 15;348(6298):245-8 [2146511.001]
  • [Cites] Science. 1991 Aug 30;253(5023):1026-8 [1887217.001]
  • [Cites] Int J Cancer. 1991 Nov 11;49(5):764-9 [1682281.001]
  • [Cites] J Infect Dis. 1991 Dec;164(6):1193-6 [1955718.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Int J Cancer. 1992 Jan 2;50(1):124-30 [1345820.001]
  • [Cites] Leukemia. 1992;6 Suppl 1:24-6 [1347800.001]
  • [Cites] J Virol. 1992 Jul;66(7):4570-5 [1351105.001]
  • [Cites] Jpn J Cancer Res. 1992 Apr;83(4):320-3 [1506264.001]
  • [Cites] J Exp Med. 1992 Oct 1;176(4):981-9 [1402668.001]
  • [Cites] Oncogene. 1992 Dec;7(12):2399-405 [1461648.001]
  • [Cites] J Virol. 1993 Mar;67(3):1211-7 [8437212.001]
  • [Cites] Blood. 1993 Aug 1;82(3):722-31 [8338942.001]
  • [Cites] J Neuropathol Exp Neurol. 1993 Jul;52(4):424-30 [8355031.001]
  • [Cites] Virology. 1993 Sep;196(1):309-18 [8356801.001]
  • [Cites] Blood. 1993 Oct 15;82(8):2501-9 [8400297.001]
  • [Cites] Jpn J Cancer Res. 1993 Aug;84(8):831-3 [8407544.001]
  • [Cites] Virology. 1993 Nov;197(1):196-204 [8212554.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):213-6 [7904671.001]
  • [Cites] Int J Cancer. 1994 Aug 1;58(3):446-51 [8050826.001]
  • [Cites] J Virol. 1994 Oct;68(10):6323-31 [8083972.001]
  • [Cites] J Virol. 1995 Feb;69(2):1328-33 [7815516.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Feb 14;92(4):1057-61 [7862633.001]
  • [Cites] Retrovirology. 2009;6:71 [19650892.001]
  • [Cites] Vet Pathol. 2009 Sep;46(5):1003-14 [19429977.001]
  • [Cites] Blood. 2009 Oct 8;114(15):3208-15 [19666871.001]
  • [Cites] J Virol. 2003 May;77(9):5286-94 [12692230.001]
  • [Cites] Blood. 2003 Jun 1;101(11):4576-82 [12560223.001]
  • [Cites] Blood. 2003 Jul 1;102(1):284-8 [12649132.001]
  • [Cites] J Long Term Eff Med Implants. 2003;13(2):127-40 [14510286.001]
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6453-7 [14559836.001]
  • [Cites] J Virol. 2004 May;78(9):4582-90 [15078940.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1357-63 [15190257.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2556-76 [15358581.001]
  • [Cites] Acta Pathol Microbiol Scand. 1969;77(4):758-60 [5383844.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Nature. 1981 Dec 24;294(5843):770-1 [6275274.001]
  • [Cites] Nature. 1983 Feb 10;301(5900):527-30 [6823332.001]
  • [Cites] Med Microbiol Immunol. 1984;173(1):57-64 [6088962.001]
  • [Cites] Jpn J Cancer Res. 1985 Feb;76(2):86-94 [2984072.001]
  • [Cites] Lancet. 1985 Aug 24;2(8452):407-10 [2863442.001]
  • [Cites] Princess Takamatsu Symp. 1984;15:121-7 [6152756.001]
  • [Cites] Lancet. 1986 May 3;1(8488):1031-2 [2871307.001]
  • [Cites] Lancet. 1986 Jul 12;2(8498):104-5 [2873363.001]
  • [Cites] Int J Cancer. 1986 Dec 15;38(6):867-75 [2878891.001]
  • [Cites] Int J Cancer. 1987 Sep 15;40(3):403-7 [2887518.001]
  • [Cites] Science. 1987 Sep 11;237(4820):1324-9 [2888190.001]
  • [Cites] Science. 1987 Sep 11;237(4820):1340-3 [2888191.001]
  • [Cites] Curr Top Microbiol Immunol. 1988;137:197-202 [3416632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 May;86(9):3351-5 [2541443.001]
  • [Cites] J Virol. 1989 Jul;63(7):3185-9 [2724422.001]
  • [Cites] Int J Cancer. 1989 Aug 15;44(2):332-6 [2759739.001]
  • [Cites] Nature. 1989 Sep 7;341(6237):72-4 [2788824.001]
  • [Cites] Am J Pathol. 1989 Dec;135(6):1025-33 [2688429.001]
  • [Cites] Mol Cell Biol. 1990 Jan;10(1):413-7 [2403646.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):383-8 [2300089.001]
  • [Cites] Leukemia. 1997 Apr;11 Suppl 3:260-2 [9209359.001]
  • [Cites] J Virol. 1998 May;72(5):3952-7 [9557681.001]
  • [Cites] Blood. 1998 Jun 15;91(12):4747-51 [9616173.001]
  • [Cites] Virology. 1998 Sep 1;248(2):332-41 [9721242.001]
  • [Cites] J Pathol. 1998 Oct;186(2):209-14 [9924438.001]
  • [Cites] J Immunol. 1999 Mar 1;162(5):2956-63 [10072546.001]
  • [Cites] J Virol. 1999 Jul;73(7):6031-40 [10364355.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3305-11 [15292059.001]
  • (PMID = 20442421.001).
  • [ISSN] 1544-2217
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / RR023965-03; United States / NCRR NIH HHS / RR / K01 RR023965; United States / NCRR NIH HHS / RR / K01 RR023965-03; United States / NCI NIH HHS / CA / P01 CA100730-08; United States / NCI NIH HHS / CA / CA100730-08; United States / NCI NIH HHS / CA / P01CA100730; United States / NCRR NIH HHS / RR / K01 RR 023965; United States / NCI NIH HHS / CA / P01 CA100730
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS278394; NLM/ PMC3147149
  •  go-up   go-down


97. Fukuda R, Hayashi A, Utsunomiya A, Nukada Y, Fukui R, Itoh K, Tezuka K, Ohashi K, Mizuno K, Sakamoto M, Hamanoue M, Tsuji T: Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc Natl Acad Sci U S A; 2005 Oct 18;102(42):15213-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL).
  • Adult T cell leukemia/lymphoma (ATLL) has been characterized as one of the most aggressive human neoplasias and its incidence is thought to be caused by both genetic and epigenetic alterations to the host cellular genes of T cells infected with human T cell leukemia virus type I (HTLV-I).
  • A multilobulated nuclear appearance is an important diagnostic marker of ATLL, and we have now identified that the molecular mechanisms underlying these formations occur through microtubule rearrangement via phosphatidylinositol 3-kinase (PI3-kinase) activation by AILIM/ICOS signaling.
  • We also show that PTEN and/or SHIP-1, which are PIP3 inositol phosphatases that inhibit the activation of downstream effectors of the PI3-kinase cascade, are disrupted in both ATLL neoplasias and in multilobulated nuclei-forming Jurkat cells.
  • This down-regulation of PTEN was found to be essential for the formation of ATLL-type nuclear lobules.
  • Furthermore, PI3-kinase and PTEN activities were observed to be closely associated with cellular proliferation.
  • Thus, our results suggest that alteration of PI3-kinase signaling cascades, as a result of the down-regulation of inositol phosphatases, induces ATLL-type multilobulated nuclear formation and is also associated with the cellular proliferation of malignant T cell leukemias/lymphomas.
  • [MeSH-major] Cell Nucleus. Leukemia-Lymphoma, Adult T-Cell. Phosphatidylinositol 3-Kinases / metabolism. Second Messenger Systems / physiology. T-Lymphocytes / cytology
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, Differentiation, T-Lymphocyte / metabolism. Cell Proliferation. Enzyme Activation. Human T-lymphotropic virus 1. Humans. Inducible T-Cell Co-Stimulator Protein. Jurkat Cells. Microtubules / metabolism. PTEN Phosphohydrolase / metabolism. Phosphoric Monoester Hydrolases / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Struct Funct. 2003 Feb;28(1):11-21 [12655146.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5441-50 [12421919.001]
  • [Cites] Nat Rev Immunol. 2003 Jul;3(7):544-56 [12876557.001]
  • [Cites] Eur J Immunol. 2003 Aug;33(8):2223-32 [12884297.001]
  • [Cites] Cell. 2003 Jul 25;114(2):201-14 [12887922.001]
  • [Cites] Hum Mol Genet. 2003 Oct 15;12 Spec No 2:R239-48 [12928488.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):691-702 [14550257.001]
  • [Cites] Int J Hematol. 2003 Nov;78(4):312-20 [14686488.001]
  • [Cites] Int Immunol. 2004 Oct;16(10):1515-22 [15339883.001]
  • [Cites] Leukemia. 2004 Nov;18(11):1839-49 [15457186.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Jpn J Clin Oncol. 1983;13 Suppl 2:165-87 [6603526.001]
  • [Cites] Jpn J Clin Oncol. 1983;13 Suppl 2:245-56 [6603533.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4524-8 [3012571.001]
  • [Cites] Jpn J Cancer Res. 1989 Mar;80(3):191-5 [2498254.001]
  • [Cites] Int J Cancer. 1990 Feb 15;45(2):237-43 [2303290.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 2;91(16):7415-9 [8052599.001]
  • [Cites] Nature. 1999 Jan 21;397(6716):263-6 [9930702.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):203-10 [10209159.001]
  • [Cites] Genes Dev. 2000 Mar 1;14(5):505-20 [10716940.001]
  • [Cites] FASEB J. 2000 May;14(7):895-903 [10783143.001]
  • [Cites] N Engl J Med. 2000 Oct 5;343(14):1020-34 [11018170.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Sep 16;276(1):335-45 [11006126.001]
  • [Cites] Trends Cell Biol. 2000 Nov;10(11):466-73 [11050418.001]
  • [Cites] Immunity. 2001 May;14(5):523-34 [11371355.001]
  • [Cites] Mol Cell. 2001 May;7(5):937-47 [11389841.001]
  • [Cites] Am J Hum Genet. 2002 Apr;70(4):829-44 [11875759.001]
  • [Cites] Curr Opin Immunol. 2002 Jun;14(3):384-90 [11973139.001]
  • [Cites] Cell Growth Differ. 2002 Jul;13(7):285-96 [12133897.001]
  • [Cites] Nat Immunol. 2003 Apr;4(4):313-9 [12660731.001]
  • (PMID = 16217039.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, T-Lymphocyte; 0 / ICOS protein, human; 0 / Inducible T-Cell Co-Stimulator Protein; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.56 / inositol-polyphosphate 5-phosphatase; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Other-IDs] NLM/ PMC1257720
  •  go-up   go-down


98. Kohno T, Yamada Y, Akamatsu N, Kamihira S, Imaizumi Y, Tomonaga M, Matsuyama T: Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells. Cancer Sci; 2005 Aug;96(8):527-33
Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible origin of adult T-cell leukemia/lymphoma cells from human T lymphotropic virus type-1-infected regulatory T cells.
  • Adult T-cell leukemia/lymphoma (ATLL) is a lymphoproliferative disorder caused by human T lymphotropic virus type 1 (HTLV-I).
  • Although ATLL cells display an activated helper/inducer T-cell phenotype, CD4+ and CD25+, they are known to exhibit strong immunosuppressive activity.
  • As regulatory T cells (Treg cells) express CD4+ and CD25+ molecules and possess potent immune response suppressive activity, we investigated a possible link between ATLL cells and Treg cells.
  • In primary ATLL cells, the expression levels of the Treg cell marker molecules Foxp3 and glucocorticoid-induced tumor necrosis factor receptor family related protein (GITR) were significantly higher than in those from healthy adults.
  • Furthermore, ATLL cells are unresponsive in vitro to concanavalin A stimulation and suppress the proliferation of normal T cells.
  • GITR mRNA expression was induced by the HTLV-I transactivator Tax, and GITR promoter analyses revealed that this induction depends on the kappaB site from -431 bp to -444 bp upstream of the putative transcription site.
  • Taken together, ATLL cells may originate from HTLV-I-infected Treg cells, and GITR seems to be involved in the progression to ATLL.
  • [MeSH-major] Leukemia-Lymphoma, Adult T-Cell / immunology. T-Lymphocytes / immunology
  • [MeSH-minor] Adult. Cell Division. Cell Line, Tumor. Concanavalin A. DNA-Binding Proteins / genetics. Forkhead Transcription Factors. Gene Expression Regulation, Neoplastic. Gene Expression Regulation, Viral. Gene Products, tax / metabolism. Glucocorticoid-Induced TNFR-Related Protein. Humans. Lymphocyte Activation. Receptors, Nerve Growth Factor / genetics. Receptors, Tumor Necrosis Factor / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108835.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors; 0 / Gene Products, tax; 0 / Glucocorticoid-Induced TNFR-Related Protein; 0 / Receptors, Nerve Growth Factor; 0 / Receptors, Tumor Necrosis Factor; 0 / TNFRSF18 protein, human; 11028-71-0 / Concanavalin A
  •  go-up   go-down


99. O'Mahony D, Debnath I, Janik J, Aisner D, Jaffe E, Waldmann T, Morris J: Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience. Leuk Lymphoma; 2008 Mar;49(3):439-46
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cardiac involvement with human T-cell lymphotrophic virus type-1-associated adult T-cell leukemia/lymphoma: The NIH experience.
  • Malignant cardiac involvement is rare in patients with human T cell lymphotrophic virus type-1-associated adult T cell leukemia/lymphoma (ATLL).
  • We report a single institution experience of eight patients with pathologically documented cardiac involvement with ATLL.
  • Cardiac involvement with ATLL was most often identified post-mortem; however, three cases were diagnosed clinically.
  • All but one of the patients had the acute or lymphomatous subtypes of ATLL and had progressed through at least one prior systemic therapy.
  • Patients with ATLL-related cardiac disease were also found to have pulmonary involvement suggesting that this may be a sign of increased risk of cardiac involvement.
  • One patient with the chronic form of ATLL remains alive 10 years after undergoing cardiac valve replacement.
  • [MeSH-major] Heart Neoplasms. Leukemia-Lymphoma, Adult T-Cell / complications
  • [MeSH-minor] Adult. Female. Human T-lymphotropic virus 1. Humans. Leukemic Infiltration. Male. Middle Aged. National Institutes of Health (U.S.). Retrospective Studies. Survival Rate. United States

  • Genetic Alliance. consumer health - Human T-cell leukemia virus type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18297519.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  •  go-up   go-down


100. Nagasaki A, Miyagi T, Taira T, Shinhama A, Kojya S, Suzuki M, Aonahata M, Yoshimi N, Takasu N: Adult T-cell leukemia/lymphoma with multiple integration of HTLV-1 provirus presenting as an isolated paranasal sinus tumor: a case report. Head Neck; 2008 Jun;30(6):815-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma with multiple integration of HTLV-1 provirus presenting as an isolated paranasal sinus tumor: a case report.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive T-cell lymphoma and etiologically associated with human T-lymphotropic virus type 1 (HTLV-1).
  • Patients with ATLL commonly present with leukemic changes, systemic lymphadenopathy, and/or extranodal lesion and have very poor prognosis.
  • METHODS AND RESULTS: We describe a rare case of ATLL presenting as an isolated paranasal mass.
  • Southern blot analysis of the biopsied specimens demonstrated multiple integration bands of HTLV-1 provirus of different intensities.
  • Thereafter, the patient showed an indolent clinical course with leukemic changes and pulmonary and cutaneous ATLL lesions and remains alive more than 5 years from diagnosis.
  • CONCLUSION: ATLL should be included in the differential diagnosis of sinonasal lymphoma, although the event is rare.
  • Multiple HTLV-1 provirus integrations of different intensities may be indicative of good prognosis for ATLL.
  • [MeSH-major] Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Proviruses / physiology
  • [MeSH-minor] Adult. Humans. Male. Virus Integration

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023035.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement